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ABSTRACT 
All the currently known breast cancer susceptibility genes are estimated to account for 
20-30% of familial breast cancer and only 5% of the total breast cancer incidence, even 
though it is suggested that the proportion of breast cancer that can be attributed to genetic 
factors may be as high as 30%. It is thus likely that there are still other breast cancer 
susceptibility genes to be found. The aim of this study was to evaluate the role of three 
DNA damage response –associated genes, ATM, RAD50, and p53, in breast cancer.  
 
ATM, a gene causative for ataxia telangiectasia (A-T), has long been a strong candidate 
for a breast cancer susceptibility gene, because of the increased breast cancer risk 
observed in obligate female heterozygous ATM mutation carriers in A-T families, and 
because of the function of the ATM kinase as a key DNA damage signal transducer 
within the genome maintenance machinery. We evaluated the role of known Finnish A-T 
–related ATM germline mutations as possible breast cancer predisposing alleles by 
analyzing their prevalence in large series of familial and unselected breast cancer cases 
from different geographical regions in Finland. Of the seven different alterations, two 
were observed in the studied familial breast cancer patients. Additionally, a third 
mutation previously associated with breast cancer susceptibility was also detected. 
Altogether, heterozygous ATM mutations were found in 6/541 familial and 7/1124 
unselected cases, compared to 1/1107 in controls, suggesting an apparent, yet overall 
limited contribution to predisposition to cancer. The results also provided evidence for 
founder effects in the geographical distribution of these mutations. Furthermore, 
functional analyses of the mutations suggested that cancer susceptibility is not restricted 
to mutations with dominant-negative effect on ATM kinase activity; haploinsufficiency 
also seems to contribute to cancer in ATM mutation carriers.  
 
As the A-T –related ATM mutations were not prevalent in Southern Finland, we also 
screened the entire coding region of the ATM gene in 47 familial breast cancer patients 
from Southern Finland and constructed haplotypes of the patients. The identified variants 
 xiii
were evaluated in additional breast cancer cases and controls. Four rare alterations were 
each found in only one patient of over 250 familial patients studied and not among 
controls. The fifth alteration studied further was found with closely similar frequencies in 
over 600 familial cases and controls. All the variants were too rare to significantly 
contribute to breast cancer susceptibility. In addition, two common ATM variants, 
5557G>A and ivs38-8T>C, previously suggested to associate with bilateral breast cancer, 
were genotyped in an extensive set of 786 familial and 884 unselected breast cancer cases 
as well as 708 healthy controls. Neither of the variants, nor any haplotype containing 
them, was significantly associated with breast cancer risk, bilateral breast cancer or 
multiple primary cancers in any of the patient groups or subgoups. Altogether, our results 
suggest only a minor effect, if any, of ATM genetic variants on familial breast cancer in 
Southern Finland.  
 
We also examined ATM expression by immunohistochemistry in breast carcinomas of 
BRCA1/2 mutation carriers as well as in familial and sporadic nonBRCA1/2 tumors to 
evaluate its role in breast tumorigenesis. ATM protein expression was aberrantly reduced 
more frequently among BRCA1- (33%) and BRCA2- (30%) tumors than in nonBRCA1/2 
tumors (10.7%). Furthermore, the nonBRCA1/2 tumors with reduced ATM expression 
were more often estrogen receptor (ER) negative, progesterone receptor (PR) negative, 
and of higher grade, and ATM was more commonly deficient in the difficult-to-treat 
ER/PR/ERBB2-triple-negative tumors than in other nonBRCA1/2 tumors.  
 
RAD50 is part of a complex important in recognizing, signaling and repairing DNA 
double-strand breaks. To evaluate the contribution of RAD50 to familial breast cancer we 
screened the whole coding region of the gene for mutations in 435 UK and 46 Finnish 
familial breast cancer cases. We identified one truncating mutation, Q350X, in one UK 
family. In addition, we screened 544 Southern Finnish familial breast cancer cases and 
560 controls for the 687delT mutation, previously identified in two Northern Finnish 
breast cancer families. It was present in 3 cases (0.5%) and 1 control (0.2%). Protein 
expression analyses suggested that RAD50 687delT is a null allele and may contribute to 
cancer through haploinsufficiency. Altogether, our results suggest that RAD50 can only 
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be making a minor contribution to familial breast cancer predisposition in UK and 
Southern Finland.  
 
The p53 R72P polymorphism has been suggested to play a role in many cancers, 
including breast cancer. We genotyped altogether 1551 Finnish familial and unselected 
breast cancer patients and 733 healthy population controls for R72P, and evaluated the 
association with breast cancer risk as well as histopathologic features of the breast tumors 
and survival of the patients. The distribution of the genotypes was similar in all groups 
studied, suggesting no association with breast cancer risk. However, unselected breast 
cancer patients with 72P homozygous genotype seemed to present more often with 
lobular carcinoma whereas R72 allele carriers had a higher frequency of ductal 
carcinomas. Survival analysis showed that unselected breast cancer patients with 72P 
homozygous genotype had significantly poorer survival than patients with other 
genotypes. This effect on survival was independent of p53 expression in the tumors, and 
multivariate analysis showed that 72P homozygous genotype was overall an independent 




Breast cancer is the most commonly occurring cancer among women, and its incidence is 
increasing worldwide. Positive family history of breast cancer is a well established risk 
factor for breast cancer, and it is suggested that the proportion of breast cancer that can be 
attributed to genetic factors may be as high as 30%. However, all the currently known 
breast cancer susceptibility genes are estimated to account for 20-30% of familial breast 
cancer, and only 5% of the total breast cancer incidence. It is thus likely that there are 
still other breast cancer susceptibility genes to be found. In addition, the model of 
polygenic susceptibility to breast cancer suggests that susceptibility to breast cancer is 
mediated through variants in many genes, each conferring a moderate risk of the disease, 
and that several common, low-penetrance susceptibility genes with multiplicative effects 
on risk may account for the residual familial aggregation of breast cancer. In addition to 
influencing breast cancer risk, variants in these genes may modify the cancer risk caused 
by other genes with which they interact, or have an impact on the progression and 
outcome of the disease, thus effecting the prognosis of the patient.  
 
Cellular responses to DNA damage are crucial for maintaining homeostasis and 
preventing the development of cancer. In addition to directly repairing DNA breaks, cells 
respond to DNA damage by halting cell-cycle progression or undergoing programmed 
cell death, apoptosis. To ensure the maintenance of the genomic integrity, cells have 
developed a highly branched DNA damage response signaling network. Defects in this 
signaling network may result in tumorigenesis. The genes operating in DNA damage 
response are thus good candidates for breast cancer susceptibility genes. This study 
focuses on the role of three DNA damage response –associated genes, ATM, RAD50 and 
p53, in breast cancer.  
 2 
2 REVIEW OF THE LITERATURE 
2.1 Cancer 
Cancer is one of the leading causes of death in the developed countries. One-fourth of the 
Finnish people will be affected with cancer at some point in their lives. The risk of cancer 
increases with age. Every year about 24 000 people in Finland are diagnosed with cancer 
(Finnish Cancer Registry, www.cancerregistry.fi); half of them will survive.  
 
Cancer is a genetic disease of somatic cells, which means that it occurs as a consequence 
of several somatic mutations in the cell. These mutations activate oncogenes (gain-of-
function) or inactivate tumor suppressor genes (loss-of-function). Proto-oncogenes 
encode proteins that are activated during cell growth, such as growth factors, membrane-
associated signaling proteins or transcription factors. When a proto-oncogene is turned on 
at an inappropriate time, it becomes an oncogene. The classic tumor suppressor genes are 
so-called gatekeeper genes: they limit cell growth by regulating basic cell functions and 
controlling cell cycle, proliferation, differentiation and apoptosis (programmed cell 
death). In addition to gatekeeper genes, two other classes of tumor suppressor genes have 
been described: caretaker genes that repair and correct errors in DNA, and landscaper 
genes that regulate the cellular microenvironment (Kinzler & Vogelstein 1997, 1998). 
When a mutation activates an oncogene or inactivates a tumor suppressor gene, it leads to 
a tendency towards uncontrolled cell growth and proliferation, which may ultimately lead 
to cancer.  
 
Most cancers have a multifactorial etiology and are attributable to a varying blend of 
genetic and environmental factors; only about 5% of common cancers are due to a strong 
inherited susceptibility (Li 1995). A minority of cancers is due to monogenic cancer 
predisposition syndromes in which there is Mendelian inheritance with incomplete 
penetrance, conferring an increased risk to a characteristic spectrum of cancers. 
Environment has the principal role in causing sporadic cancer, and inherited genetic 
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factors make only a minor contribution to susceptibility to most types of cancer. 
Significant effects of heritable factors have been observed for prostate cancer, where 
approximately 40% of the risk may be explained by heritable factors, colorectal cancer 
(35%) and breast cancer (30%) (Lichtenstein et al. 2000). In most of the known cases so 
far, inherited cancer predisposition occurs because of the germline alterations in tumor 
suppressor genes. This inherited cancer predisposition usually shows dominant 
inheritance at the family level, but is recessive on the cellular level. One mutated allele is 
inherited; however, according to the classic two-hit hypothesis (Knudson 1971), tumor 
development requires two mutated alleles. The second hit is a somatic mutation in the 
wild-type allele resulting in two mutated alleles and loss of function of the tumor 
suppressor. Loss of heterozygosity (LOH) is a common way to lose the wild-type allele 
and has been a hallmark of a tumor suppressor gene. In addition to the classic two-hit 
hypothesis, other mechanisms, with which mutated tumor suppressor genes can cause 
cancer, are emerging: dominant-negative effect (Brachmann et al. 1996, Chenevix-
Trench et al. 2002) and haploinsufficiency (Fero et al. 1998, Venkatachalam et al. 1998, 
Kwabi-Addo et al. 2001, reviewed in Fodde & Smits 2002). In the former, the mutated 
allele disturbs the function of the normal allele; in the latter, one normal allele is not 
sufficient for the proper function of the gene. In both cases, losing both normal alleles is 
not necessary for tumor progression.  
2.2 Breast cancer 
2.2.1 Epidemiology 
Breast cancer is the most commonly occurring cancer among women, and its incidence is 
increasing worldwide. The estimated annual incidence of breast cancer worldwide is over 
one million cases, and there is a significant regional difference in the incidence rates: the 
high-risk areas North America and Northern Europe account for 16% of the worldwide 
population but 60% of the worldwide incidence of breast cancer (Parkin 2004, Parkin et 
al. 2005). In Finland, over 4000 women were diagnosed with breast cancer in 2006 
(estimate based on 2005 incidence, Finnish Cancer Registry, www.cancerregistry.fi). 
Incidence rates also correlate with gender, ethnicity, and age. Approximately only one 
 4 
out of every 150 breast cancers occurs in males (20 men were diagnosed in Finland in 
2005.). Breast cancer incidence in women increases up to 10-fold from age 25 to age 40. 
In addition to demographic factors, numerous other risk factors have been identified. 
These include among other things older age at menopause, early age of menarche, 
nulliparity and older age at first child birth, no breast feeding, low physical activity, use 
of oral contraceptives or hormone replacement therapy, obesity in postmenopausal 
women, alcohol use, and high intake of unsaturated fat and well-done meat (reviewed in 
Oldenburg et al. 2007). Positive family history of breast cancer is a well established risk 
factor for breast cancer, with first-degree relatives of patients having approximately two-
fold elevated risk. In Western countries, the overall lifetime risk for women who have no 
affected relative is 7.8%, for those who have one, the risk is 13.3%, and for those who 
have two, the risk is 21.1% (Collaborative Group on Hormonal Factors in Breast Cancer 
2001).  
 
Although breast cancer incidence is increasing, the prognosis has improved, partly 
because of earlier diagnosis and partly as a result of the use of adjuvant therapies. Four 
types of standard treatment are used for breast cancer: surgery, radiation therapy, 
chemotherapy and hormone therapy. Radiation therapy, chemotherapy, and hormone 
therapy are often used as adjuvant therapy with surgery.  
2.2.2 Clinical and molecular features 
Virtually all breast tumors are carcinomas, tumors derived from epithelial tissue. 
Carcinomas are the most common type of cancer. Breast cancers are typically 
adenocarcinomas, derived from glandular tissue, and can be classified into 
histopathologic subtypes with distinct biological and prognostic characteristics. 
Histologically the most common breast tumors are infiltrating ductal (70%) and lobular 
(6%) carcinomas. Both are derived from the terminal duct lobular unit (TDLU) 
(Sainsbury et al. 2000). Medullary carcinomas represent a minor (about 3% of breast 
cancer) morphologically and biologically distinct group characterized by lymphocyte 
infiltrates in the tumor periphery. In the clinical practice breast cancer patients are 
classified in stages based on the clinical and pathologic extent of the disease according to 
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the TNM system, where T refers to tumor size, N to the presence of metastases in the 
local regional lymph nodes, and M to distant metastases. Breast tumors are graded and 
classified histologically based on an assessment of tubule/gland formation, nuclear 
pleomorphism and mitotic counts as well differentiated (grade 1), moderately 
differentiated (grade 2), and poorly differentiated (grade 3). Both the TNM classification 
and histological grade are significantly associated with survival and are thus powerful 
prognostic factors (Sainsbury et al. 2000). Approximately 30% of breast tumors have 
mutations in the p53 tumor suppressor gene, often accompanied by loss of the wild-type 
allele (Børresen-Dale 2003). As most p53 missense mutations cause accumulation of the 
p53 protein in the tumor cells, immunohistochemisty is widely used to detect p53 
mutations in breast tumors. Hormone receptor (estrogen receptor, ER and progesterone 
receptor, PR) positive breast cancers account for 75-80% of all breast cancers, and 
hormone receptor expression is associated with better prognosis due to good response to 
targeted hormone treatments/adjuvant hormone therapy (Duffy 2005). Overexpression or 
amplification of ERBB2 (HER2), a member of a receptor tyrosine kinase superfamily, is 
associated with aggressiveness and a poor prognosis in breast cancer (Menard et al. 2000, 
Yarden 2001). However, ERBB2-positive breast cancers can be treated with targeted 
therapy with trastuzumab (Herceptin), an antibody directed against the ERBB2 
ectodomain, specifically inhibiting the growth of cells expressing ERBB2 (Duffy 2005). 
ERBB2-positive cases account for 15-20% of breast cancer cases. Ten to fifteen per cent 
of breast cancers are so-called triple-negative breast cancers, lacking expression of all 
these three receptors (Cleator et al. 2007).  
 
Until recently, the subclassification of breast carcinomas has been based on cellular 
morphology and the presence of receptors such as ER, PR and ERBB2, identified by 
immunohistochemical staining. Very recently, however, cDNA microarray-based gene 
expression profiling has become a new classification tool, and five distinct types of breast 
cancers have been defined according to similarities in gene expression patterns (Perou et 
al. 2000, Sorlie et al. 2001). These include two ER-positive groups, luminal subtypes A 
and B, with features shared with luminal epithelial cells arising from the inner layer of 
the duct lining. The third group overexpresses ERBB2, and the fourth group is a normal 
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breast gene expression group, characterized by high expression of basal epithelial genes 
and low expression of luminal epithelial genes. The fifth group is the basal-like subgroup 
sharing features with normal breast basal epithelial cells, characterized by expression of 
basal (myoepithelial) cytokeratins 5/6 and 17, and absence of ER, PR and ERBB2 
expression. These tumors are assumed to arise from the outer (basal) layer of breast duct 
(myoepithelial cells).  
2.3 Breast cancer genetics 
2.3.1 High-penetrance breast cancer susceptibility genes 
2.3.1.1 p53, PTEN and LKB1 
Breast cancer is a characteristic in certain rare autosomal dominant cancer predisposition 
syndromes. Li-Fraumeni syndrome (LFS) (Li & Fraumeni 1969) is characterized by 
childhood soft tissue sarcomas and osteosarcomas, brain tumors, breast cancer, and 
adrenocortical as well as pancreatic carcinomas. Mutations in the p53 tumor suppressor 
gene account for approximately 70% of families fulfilling the classical criteria for LFS 
(Malkin et al. 1990, Birch et al. 1994, Frebourg et al. 1995 Varley et al. 1997). 
Altogether, nearly 400 families with germline p53 mutations have been reported 
worldwide. It is estimated that 28-56% of p53 mutation carrier women will develop 
breast cancer by the age of 45 years (Garber et al. 1991, Chompret et al. 2000).  
 
Cowden syndrome (CS) is caused by germline mutations in the tumor suppressor gene 
PTEN: mutations in PTEN are present in about 80% of CS families (Liaw et al. 1997). CS 
is associated with benign and malignant tumors of the breast, thyroid and endometrium as 
well as multiple hamartomas of the skin, gastrointestinal tract, and central nervous 
system. Women with CS have a 20-50% lifetime risk of breast cancer (Eng 2003).  
 
Germline mutations in LKB1 (STK11) tumor suppressor gene predispose to Peutz-Jeghers 
syndrome (PJS) (Hemminki et al. 1998) characterized by hamartomatous polyps of the 
gastrointestinal tract and melanine pigmentation of the lips as well as increased risk of 
various cancers, particularly of gastrointestinal, breast, gynecologic, and pancreatic 
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tumors. The risk of breast cancer in PJS by the age of 70 is up to 50% (Hearle et al. 
2006).  
2.3.1.2 BRCA1 and BRCA2 
BRCA1 and BRCA2 are caretaker genes that act as sensors of DNA damage and 
participate in the DNA repair processes. BRCA1 functions in DNA repair, protein 
ubiquitylation, chromatin remodeling, and cell-cycle checkpoint control; BRCA2 is 
involved in DNA double-strand break (DSB) repair through homologous recombination 
(HR) (Powell & Kachnic 2003, Yoshida & Miki 2004, Boulton 2006). Their inactivation 
thus allows other genetic defects to accumulate and leads to genetic instability. Both 
BRCA1 (Miki et al. 1994) and BRCA2 (Wooster et al. 1995) are high-penetrance breast 
cancer susceptibility genes. Approximately 85% of breast cancer mutations in BRCA1 
and BRCA2 are frameshift or nonsense mutations leading to truncated protein products. 
LOH is a common phenomenon in both BRCA1 and BRCA2 tumors (reviewed in 
Honrado et al. 2005a and 2006), supporting the roles of BRCA1 and BRCA2 as classical 
tumor suppressor genes. Germline mutations in BRCA1 and BRCA2 confer strong 
lifetime risks of breast and ovarian cancer. The average cumulative risk of breast cancer 
at the age of 70 years for BRCA1 and BRCA2 mutation carriers has been estimated to be 
up to 80%, and the risk of ovarian cancer up to 60% for BRCA1 and 40% for BRCA2 
mutation carriers (Ford et al. 1994, 1998, Easton et al. 1995, The Breast Cancer Linkage 
Consortium 1999, Risch et al. 2001, Antoniou et al. 2003, Marroni et al. 2004). 
Dependence of the risk on ethnicity, family history, specific mutation, and other 
modifying genes has been suggested. BRCA1 and BRCA2 mutations are found in about 
45% of families with breast and ovarian cancer, while the mutation rate in families with 
only breast cancer ranges from 10-15% (for families with three breast cancers) to 25–
35% (for families with more than five breast tumors) (Vahteristo et al. 2001, Honrado et 
al. 2005a). BRCA2 mutations are also associated with male breast cancer. In addition, 
biallelic BRCA2 mutations cause Fanconi anemia subtype FA-D1 and predispose to 
childhood malignancies (Howlett et al. 2002). Fanconi anemia is a rare, recessive, 
chromosomal instability disorder characterized by growth retardation, congenital 
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malformations, progressive bone marrow failure, cancer predisposition, and cellular 
hypersensitivity to DNA cross-linking agents.  
 
Breast cancer tumors arising in BRCA1 mutation carriers have been shown to associate 
with distinct histopathologic features (reviewed in Honrado et al. 2005a and 2006). 
BRCA1 –associated tumors are generally of higher grade and more often ER and PR 
negative than sporadic or familial nonBRCA1/2 tumors, and ERBB2 overexpression is 
very infrequent in BRCA1 carcinomas. The majority of BRCA1 tumors are infiltrating 
ductal carcinomas, but there is a significantly higher frequency of medullary tumors 
among BRCA1 tumors than in non-carrier tumors. BRCA1 tumors are also associated with 
positive p53 immunostaining and somatic p53 mutations more frequently than 
nonBRCA1/2 tumors. Furthermore, most BRCA1 tumors have a basal-like gene 
expression profile, characterized by expression of basal cytokeratins, overexpression of 
epidermal growth factor receptor (EGFR), and absence of ER, PR and ERBB2 expression 
(Sorlie et al. 2003, Foulkes et al. 2003, Palacios et al. 2004). On the contrary to BRCA1 
tumors, no clear histopathologic subtype specifically differentiating BRCA2 tumors has 
been found, although studies on somatic genetic changes, gene expression profiles, and 
immunohistochemistry have revealed some differences in characteristics of BRCA2 
tumors compared to tumors of non-carriers (Tirkkonen et al. 1997, Hedenfalk et al. 2001, 
Honrado et al. 2006a, 2006b).  
2.3.2 Low-penetrance breast cancer susceptibility genes 
2.3.2.1 CHEK2 
Checkpoint kinase 2 (CHEK2) is an important signal transducer within the cellular 
network that responds to DNA damage and protects genomic integrity (Bartek et al. 
2001). CHEK2 1100delC variant was the first low-penetrance variant associated with 
familial breast cancer, and the first variant identified conferring a moderate risk of breast 
cancer (Meijers-Heijboer et al. 2002, Vahteristo et al. 2002). The frequency of 1100delC 
varies between different populations, but it is relatively low in all populations studied 
(highest frequencies in the Netherlands, 1.3-1.6%, and in Finland, 1.1-1.4%; not detected 
at all in the Spanish population). It is estimated to confer an approximately two-fold 
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increased risk of breast cancer, and the carriers of 1100delC also have an elevated risk of 
bilateral breast cancer (reviewed in Nevanlinna & Bartek 2006). Other variants in 
CHEK2 have also been considered to be involved in causing breast cancer risk, and at 
least the I157T variant seems to be associated with breast cancer risk, but the risk is 
probably lower than that associated with 1100delC (Cybulski et al. 2004, Kilpivaara et al. 
2004). Variants in CHEK2 have also been associated with increased risk of prostate and 
colorectal cancer (Seppälä et al. 2003, Cybulski et al. 2004a, 2004b, 2006, Kilpivaara et 
al. 2006).  
2.3.2.2 PALB2 and BRIP1 
A new BRCA2 binding protein, PALB2, was recently identified. PALB2 colocalizes with 
BRCA2 in nuclear foci, promotes its localization and stability in key nuclear structures, 
such as chromatin and nuclear matrix, and enables its recombinational repair and 
checkpoint functions (Xia et al. 2006). More recently, truncating germline mutations in 
PALB2 were found to be associated with familial breast cancer, conferring a two- to four-
fould increased breast cancer risk (Rahman et al. 2007, Erkko et al. 2007). Pathogenic 
mutations in PALB2 were also identified in families affected with Fanconi anemia and 
cancer in early childhood, demonstrating that biallelic PALB2 mutations cause a new 
subtype of Fanconi anemia, FA-N, and, similar to biallelic BRCA2 mutations, confer a 
high risk of childhood cancer (Reid et al. 2007, Xia et al. 2007).  
 
The BRCA1 associated C-terminal helicase, BACH1 (also known as BRIP1), a protein 
binding directly to the BRCA1 BRCT domains and participating in DNA double-strand 
break repair with BRCA1 (Cantor et al. 2001), has been shown to be the protein defective 
in another Fanconi anemia subtype, FA-J (Levran et al. 2005, Litman et al. 2005). 
Recently, truncating mutations in BRIP1 were also identified as breast cancer 
susceptibility alleles, conferring a two-fold increased risk of breast cancer (Seal et al. 
2006).  
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2.3.3 Common polymorphisms associated with breast cancer risk 
All the currently known breast cancer susceptibility genes are estimated to account for 
20-30% of familial breast cancer (Figure 1) and only 5% of the total breast cancer 
incidence, even though it is suggested that the proportion of breast cancer that can be 
attributed to genetic factors may be as high as 30%. It is thus likely that there are still 
other breast cancer susceptibility genes to be found (Oldenburg et al. 2007). In addition, 
the model of polygenic susceptibility to breast cancer suggests that susceptibility to breast 
cancer is mediated through variants in many genes, each conferring a moderate risk of the 
disease, and that several common, low-penetrance genes with multiplicative effects on 
risk may account for the residual nonBRCA1/2 familial aggregation of breast cancer 
(Pharoah et al. 2002, Antoniou et al. 2002, Antoniou & Easton 2006). Linkage studies 
have also suggested putative other breast cancer susceptibility loci but the genes have not 
been identified so far, and attempts to identify new breast cancer susceptibility genes 
through candidate gene approach have not, despite the few exceptions, been very 
successful. As linkage studies lack power to detect alleles with moderate effects on risk, 
large case-control association studies are required (Easton et al. 2007).  
 
During the past 10 years, case-control association studies have been used widely in the 
search for breast cancer susceptibility alleles, and most of these studies have focused on 
putative functional variants, including single nucleotide polymorphisms (SNPs), in genes 
that are candidates for breast cancer susceptibility genes because of their known 
biological functions, such as genes involved in DNA repair. However, most associations 
reported have not been confirmed by subsequent studies. This situation probably reflects 
the fact that most initial findings are false positives. On the other hand, as many studies 
lack the power to detect genetic variants that are associated with modest increases in risk, 
nonreplication may also occur because of a lack of adequate statistical power in the 
replication study, resulting in false negatives (Breast Cancer Association Consortium 
2006).  
 
Recently, the Breast Cancer Association Consortium (BCAC) found evidence of an 
association with breast cancer for D302H variant in caspase 8 (CASP8) and L10P variant 
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in transforming growth factor beta (TGFB1) (Cox A et al. 2007). They estimated that the 
variants in CASP8 and TGFB1 may account for approximately 0.3% and 0.2% of the 
excess familial risk of breast cancer, respectively, in populations of European ancestry. 
These data are the strongest evidence to date for common breast cancer susceptibility 
alleles. In CASP8, the histidine allele of D302H is associated with a moderate reduction 
in breast cancer risk. This SNP was initially identified through a candidate gene 
approach, as CASP8 is an important initiator of apoptosis and is activated by external 
death signals and in response to DNA damage (Chipuk & Green 2006). However, further 
experiments are required to establish whether D302H itself, or another variant in strong 
linkage disequilibrium with it, is causative, as the functional consequences of the aspartic 















Figure 1. Contribution of known breast cancer susceptibility genes to the overall genetic 
factors involved in breast cancer (Adapted from Willems 2007).  
 
In addition to attempts to identify common risk variants through candidate gene 
approach, SNPs are used in genome-wide association studies. Recently, BCAC 
conducted a large two-stage genome-wide association study followed by a third stage in 
which 30 SNPs were tested for confirmation, and five novel independent loci with strong 
and consistent evidence of association with breast cancer were found (Easton et al. 2007). 
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Further studies are needed to identify which genes and variants are the actual causative 
ones for breast cancer risk.  
 
Common polymorphisms may also modify the cancer risk caused by mutations in the 
genes with which they interact. The penetrance of BRCA1 and BRCA2 mutations, for 
example, seems to depend on the family history, and the risks have been found to vary by 
age at diagnosis and the type of cancer of the index patient. These observations would be 
consistent with the hypothesis that the breast cancer risk of the mutation carriers is 
modified by other genetic factors (Antoniou & Easton 2006). The modifying effect would 
explain the differences between population-based estimates for BRCA1/2 penetrance and 
estimates based on high-risk families (Antoniou et al. 2002). So far, the attempts to 
identify the genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers have 
yielded modest results: the studies have been small and the subsequent studies have failed 
to replicate the results (Chenevix-Trench et al. 2007). A single nucleotide polymorphism 
in the 5'UTR of RAD51, 135G>C, is the most convincing candidate as a modifier of 
BRCA1/2. RAD51 is an important component of DNA double-strand break repair 
mechanisms that interacts with both BRCA1 and BRCA2. The 135G>C SNP was 
initially suggested as a possible modifier of breast cancer risk in BRCA1 and BRCA2 
mutation carriers (Wang et al. 2001). Subsequent studies have confirmed that 135G>C 
modifies the risk of breast cancer in BRCA2 mutation carriers, but not in BRCA1 
mutation carriers (Levy-Lahad et al. 2001, Kadouri et al. 2004, Antoniou et al. 2007). To 
generate sufficient statistical power to reliably identify modifier genes of BRCA1 and 
BRCA2, the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA) 
has recently been established (Chenevix-Trench et al. 2007).  
 
In addition to breast cancer susceptibility, genetic variation may play a role in the 
progression of the disease, affecting its aggressiveness, response to treatments, and 
overall outcome. The overall impact of genetic factors, including those yet to be 
discovered, on breast cancer outcome remains unclear, but given the implications to 
treatment, follow-up, and patient counseling, this is a field that deserves extensive 
studying.  
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2.4 ATM and the MRN complex 
2.4.1 ATM structure 
The ATM (Ataxia Telangiectasia Mutated) gene extends over 160 kb of genomic DNA on 
chromosome 11q22.3 and produces an approximately 13 kb transcript. It comprises of 66 
exons, 62 of which encode a 350 kDa protein expressed in multiple embryonic and adult 
tissues (Savitsky et al. 1995, Chen & Lee 1996). ATM is a serine/threonine kinase 
belonging to the phosphoinositide 3-kinase (PI3-kinase) –like family present in 
organisms from mammals to yeast. ATM is included in a subgroup of these kinases 
termed PI3-kinase-like kinases (PIKK) (Abraham 2004). The conserved PI3-kinase 
domain is located towards the C-terminus of the ATM protein (Figure 2). In addition to a 
leucine zipper of an unknown function and an ATP binding site, the ATM protein 
contains two other domains, FAT and FATC (Bosotti et al. 2000). The FAT domain is 
named after three groups of proteins sharing this domain, FRAP (mTOR), ATM and 
TRRAP. The most C-terminal domain is called FATC, since this domain is found only in 
combination with FAT. It is suggested that these domains fold together in a configuration 
that ensures efficient function of the protein kinase domain (Lavin et al. 2004). In 
addition to the kinase domain, a second substrate-binding site, suggested to bind p53, 
BRCA1 and BLM, has been mapped to the N-terminus of ATM.  












Figure 2. Structure of ATM (Adapted from Lavin et al. 2004.). 
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In proliferating cells ATM is largely a nuclear protein, which is in line with its function 
in DNA damage recognition and cell-cycle checkpoint signaling, but approximately 10% 
of the protein is extranuclear, present in cytoplasmic vesicles (Lavin et al. 2004).  
2.4.2 Structure of the MRN complex 
The highly conserved MRE11/RAD50/NBS1 (MRN) complex has a central role in many 
cellular responses to DNA double-strand breaks (DSBs), including homologous 
recombination (HR), non-homologous end-joining (NHEJ), telomere maintenance, and 
DNA damage checkpoint activation (Assenmacher & Hopfner 2004). The complex 
consists of the large coiled-coil ATP-binding cassette (ABC) ATPase RAD50, the 
exonuclease MRE11, and the checkpoint mediator NBS1. The exonuclease MRE11 
forms the core of the complex directly binding NBS1, DNA, and RAD50. The core 
MRE11-RAD50 (MR) complex exists as a heterotetrameric assembly (M2R2) with two 
globular DNA binding heads (Hopfner et al. 2001) (Figure 3a). RAD50 employs its ABC 
ATPase, zinc-hook, and coiled coils to bridge DSBs and facilitate DNA end processing 
by MRE11. Contributing to the regulatory roles of the MRN complex, NBS1 harbors N-
terminal phosphopeptide-interacting FHA and BRCT domains, as well as C-terminal 

































Figure 3. MRN complex and RAD50 (Adapted from Williams et al. 2007). 
a) Structure and protein-protein and protein-nucleic acid interactions of the MRN 
complex. 
b) Structure of RAD50. 
 
RAD50 is a 1312 amino acid protein that contains two ABC-ATPase domains separated 
by two coiled-coil regions required for intramolecular interactions. A Cys-X-X-Cys motif 
of the zinc-hook structure located in the middle of the coiled-coil domain functions as a 
dimerization domain between two RAD50 arms (Hopfner et al. 2002, van den Bosch et 
al. 2003) (Figure 3b).  
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2.4.3 Function of ATM and the MRN complex in DNA damage 
response 
Cellular responses to DNA damage are crucial for maintaining homeostasis and 
preventing the development of cancer. DNA damage response (DDR) is a complex, 
highly branched signaling network protecting the stability and integrity of the cellular 
genome (Shiloh 2006). Of the many kinds of DNA lesions, double-strand breaks (DSBs) 
are particularly effective in triggering DDR. DSBs are induced by ionizing radiation (IR) 
as well as by oxygen radicals formed in the normal metabolism. They are also a part of 
normal genomic transactions such as DNA replication and meiosis (Khanna & Jackson 
2001). Failure to repair DSBs can lead to gross chromosomal rearrangements and 
ultimately to tumorigenesis. An ongoing DSB response has been observed in 
precancerous cells and tumor tissues (Gorgoulis et al. 2005, Bartkova et al. 2005a, 
2005b). Two mechanisms are used in eukaryotic cells to repair DSBs: non-homologous 
end-joining (NHEJ) ligating free DNA ends and homologous recombination (HR) 
between sister chromatids. NHEJ acts throughout the cell cycle (Lieber et al. 2004, 
2006), but HR is a high-fidelity process functioning in the late S and G2 phases of the 
cell cycle (Wyman et al. 2004).  
 
In addition to directly repairing DNA breaks, cells respond to DNA damage by halting 
cell-cycle progression or undergoing programmed cell death, apoptosis (Kastan & Bartek 
2004). To ensure that an earlier process, such as DNA replication or mitosis, is complete, 
and that the genomic integrity is maintained before cell-cycle progression, cells have 
developed a surveillance mechanism based on an intricate network of protein kinase 
signaling pathways that lead to cell-cycle delay or arrest in response to DNA damage at 
G1/S, intra-S, and G2/M checkpoints (Hartwell & Weinert 1989, Zhou & Elledge 2000). 
These cell-cycle checkpoints are central to the maintenance of the genomic integrity and 
basic viability of the cells, and defects in these pathways may result in tumorigenesis.  
 
ATM is the initiator of the signaling cascades responding to DSBs. (Shiloh 2003, 2006). 
ATM is normally present in cells as an inactive dimer or multimer complex. After DNA 
damage, ATM undergoes autophosphorylation on Ser1981 and the inactive complex 
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dissociates into active monomers (Bakkenist & Kastan 2003). Once activated, ATM 
directly or indirectly phoshorylates over 30 substrates (Lavin et al. 2006), leading to 
activation of cell-cycle checkpoints and initiation of DNA repair. These substrates 
include DNA damage sensors, checkpoint mediators, signal transducers as well as the 
effectors directly executing the DDR and DNA repair functions (Kastan & Bartek 2004, 
Lavin & Kozlov 2007) (Figure 4). Many components of the signaling network 
downstream of ATM are themselves capable of activating several other downstream 
effectors, which amplifies the signal in the cascade. A remarkable feature of ATM 
function is its ability to approach the same endpoint from many directions by using 
different pathways (Shiloh 2003, 2006). In addition, the same effectors can be targeted by 
several different ATM-dependent mechanisms. A prominent example is the G1/S 
checkpoint, just before the entry into the S-phase, where p53 is in central role. ATM 
directly phosphorylates p53 on Ser15 and other sites, thus contributing to its stabilization 
and transcriptional activation. ATM also phosphorylates three other proteins, CHEK2, 
MDM2 and MDMX, all of which also influence the stability and transcriptional activity 
of p53 (Kastan & Lim 2000, Lavin & Kozlov 2007). CHEK2 activation by ATM leads to 
phosphorylation of p53 by CHEK2. This and direct phosphorylation of p53 as well as 
phosphorylation of MDM2 by ATM interferes the binding of p53 to MDM2, leading to 
stabilization and transcriptional activation of p53. Transcriptionally activated p53 then 
induces p21/WAF1, an inhibitor of cyclin-dependent kinases, to inhibit cyclin E/CDK2, 
leading to inability of cells to progress from G1 to S-phase (Kastan & Bartek 2004, Lavin 
& Kozlov 2007). This p53-dependent pathway is the dominant checkpoint response to 
DNA damage in mammalian cells in G1 phase and may lead to sustained G1 arrest 
(Bartek & Lukas 2001, Kastan & Bartek 2004). The other pathway activated by ATM 
leading to the G1 checkpoint is a rapid transient pathway that is p53-independent. In this 
pathway the phosphorylation of CHEK2 by ATM leads to upregulation of CHEK2. The 
phosphorylation of CDC25A by CHEK2 then stimulates the degradation of CDC25A 
preventing CDC25A-dependent dephoshorylation and activation of CDK2 (Falck et al. 
2001), leading to G1 arrest. This pathway is not only involved in the rapid prevention of 
S-phase entry in the G1 checkpoint but also in the transient intra-S-phase response to 
DNA damage (Bartek & Lukas 2001, Falck et al. 2002).  
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ATM also phosphorylates various other proteins involved in the control of S-phase, such 
as NBS1, BRCA1, SMC1 and FANCD2 (Kastan & Bartek 2004, Lavin & Kozlov 2007 
and the refs. therein). In addition to the CDC25A-pathway, another ATM-dependent 
pathway, NBS1/BRCA1/SMC1 pathway, is also involved in the control of the intra-S-
phase checkpoint (Falck et al. 2002, Kitagawa et al. 2004). SMC1 controls DNA 
replication forks and assists in DNA repair, and the phosphorylation of SMC1 by ATM 
requires the checkpoint mediators NBS1 and BRCA1 (Kitagawa et al. 2004). 
Phosphorylation of FANCD2 by ATM is also involved in the control of this checkpoint 
(Taniguchi et al. 2002).  
 
ATM is also involved in the regulation of the G2/M checkpoint before mitosis, which is 
controlled by the interacting ATM/CHEK2 and ATR/CHEK1 pathways. Under normal 
conditions, the dephosphorylation of CDC2 by CDC25C allows cyclin B/CDC2 to 
promote mitotic entry. ATM-dependent phosphorylation of CDC25C by CHEK2 thus 
inhibits mitotis-promoting activity of cyclin B/CDC2. The checkpoint mediators BRCA1 
and 53BP1 are also needed in the G2/M checkpoint. BRCA1 is phosphorylated by ATM 
and plays a role in CDC25C regulation. It also activates CHEK1, which in turn blocks 
mitotic entry through phosphorylation of CDC25C (reviewed in Kastan & Bartek 2004 
and Lavin & Kozlov 2007). In addition, phoshorylated BRCA1, together with BRCA2, 
induces DSB repair using HR, in part through the activation of the DNA-repair enzyme 
































Figure 4. A simplified overview of the central players in ATM-regulated cell-cycle 
checkpoint pathways. 
 
The MRN complex has a critical role in DSB recognition, stabilization and signaling. It 
acts as a sensor of DSBs and regulates chromatin remodeling near them. The MRN 
complex also initiates cell-cycle checkpoint signaling cascades through ATM activation. 
This is a two-way functional interaction, as the members of the complex are also 
downstream of ATM in these pathways (Lavin 2004). The early stages of DSB response 
are characterized by the rapid formation of nuclear foci at the damaged sites of the 
chromatin, representing huge conglomerates of recruited DDR proteins that gather 
together through repeated protein-protein interactions (Shiloh 2006). ATM is present in 
the nuclear foci at DSB sites, together with other DDR proteins MDC1, 53BP1, BRCA1 
and the MRN complex (Bekker-Jensen et al. 2006). The MRN complex is the first to bind 
to DSB sites. It acts as a DSB sensor for ATM and recruits it to the damaged sites. The 
activation of ATM requires a physical interaction between ATM and the MRN complex 
and DNA (Uziel et al. 2003, Lee & Paull 2004, 2005, Paull & Lee 2005, Dupré et al. 
2006). The MRN component binding ATM is NBS1, which has a role in chromatin 
structure modulation (You et al. 2005, Berkovich et al. 2007). MRN complex is followed 
by MDC1, whose binding to chromatin requires phosphorylation of histone H2AX by 
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ATM. Phosphorylated H2AX (γH2AX) has an important role in anchoring DDR proteins 
to the damaged sites (Fernandez-Capetillo et al. 2004). MDC1 is required for ATM 
recruitment and also for sustained interaction with damaged DNA (Mochan et al. 2003, 
2004, Lou et al. 2006), as it is required for sustained binding of MRN and 53BP1 (Lukas 
et al. 2004, Bekker-Jensen et al. 2005), coming next after MDC1, to the damaged 
chromatin. 53BP1 is also needed for ATM activation (Mochan et al. 2003, 2004). MDC1, 
53BP1 and NBS1 are all targets of ATM-dependent phosphorylation and were thus 
initially placed downstream of ATM. However, recent data have shown that these 
proteins function also upstream of ATM, being also activators and not only sensors 
upstream of transducers. The initiation of DDR is now viewed as a cyclic process 
amplifying the signal, and the signal amplification process depends on the interaction of 
the sensors and activators with damaged chromatin and ATM (Shiloh 2006).  
2.4.4 Ataxia-telangiectasia 
Biallelic mutations in the ATM gene cause ataxia-telangiectasia (A-T) (Savitsky et al. 
1995). A-T is an autosomal recessive disease with an estimated frequency of 1:40 000-
300 000. It is an early-onset progressive neurologic disorder characterized by progressive 
cerebellar ataxia, ocular apraxia, telangiectasias in eyes, ears and cheeks, radiosensitivity, 
immunodeficiency, and increased risk of cancer, particularly of lymphoma and leukemia 
(Lavin et al. 1997). A-T patients have a lifetime cancer risk of 30-40%. The most 
common malignancies are tumors of the immune system that occur in the first 15 years of 
life; and epithelial cancers, including breast cancer, are seen in adults. A-T patients 
usually die from respiratory failure or cancer; median life expectancy is approximately 30 
years. Genetic instability is a hallmark of the A-T phenotype. Typical cellular features of 
A-T patients include increased radiosensitivity, cell-cycle checkpoint defects, and an 
increased level of spontaneously occurring chromosome aberrations in both lymphoid 
and non-lymphoid cells (Meyn 1999).  
2.4.5 ATM and breast cancer 
ATM has long been considered as a good candidate gene for breast cancer susceptibility. 
It is a major activator of cellular responses to DNA double-strand breaks, interacting with 
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other central players in the DNA damage response pathways, including also known breast 
cancer susceptibility genes, such as BRCA1, p53, and CHEK2. Furthermore, the function 
of the ATM protein makes it a good candidate for a role in breast cancer predisposition, 
as radiation exposure is associated with an increased risk of breast cancer (Khanna & 
Chenevix-Trench 2004). The first suggestion that ATM might be a breast cancer 
susceptibility gene came from studies reporting an increased breast cancer risk among 
obligate heterozygous mutation carriers in A-T families (Swift et al. 1987, 1991). An 
increased risk for malignancy, in particular, female breast cancer, among individuals 
heterozygous for germline ATM mutations in A-T families has been reported in many 
studies (Olsen et al. 2001, Thompson et al. 2005), but in a recent study, the increased 
breast cancer risk of the heterozygous mutation carriers in A-T families was seen only in 
the mothers of the A-T patients (Olsen et al. 2005).  
 
On the basis of estimated A-T carrier frequency of 1% and an increased risk of breast 
cancer of about three-fold in obligate heterozygous mutation carriers in A-T families, it 
was initially suggested that A-T heterozygosity could account for as much as 5% of all 
breast cancer (Easton 1994). However, the role of ATM as a breast cancer susceptibility 
gene outside the A-T families has remained controversial, as many of the case-control 
studies have failed to show an elevated frequency of ATM mutations in breast cancer 
patients. A number of studies have searched for germline ATM mutations in breast cancer 
cases and compared the frequencies between breast cancer cases and population controls 
(reviewed in Khanna & Chenevix-Trench 2004 and Ahmed & Rahman 2006, see also 
6.1.1), but the evidence regarding the role of ATM as a breast cancer susceptibility gene 
has been contradictory. One suggested reason for the discrepancy is that analysis of 
breast cancer cases unselected for family history would be an inefficient way to detect 
ATM mutations if they did confer the high increased risk of breast cancer initially 
suggested; analysis of multiple-case breast cancer families could be more successful 
(Khanna & Chenevix-Trench 2004). On the other hand, as the frequency of ATM 
mutations found in breast cancer patients in the general population has been low, many of 
the mutations are too rare to be easily evaluated in case-control studies. In addition, 
recent epidemiologic analyses suggest approximately two-fold increase of breast cancer 
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risk for heterozygous ATM mutation carriers in A-T families (Thompson et al. 2005), and 
most of the case-control studies have been too small to detect modest increases of risk 
associated with ATM variants. Furthermore, very few studies have screened the whole 
ATM gene in both cases and controls, thereby limiting the ability to directly compare the 
frequency and type of identified variants (Ahmed & Rahman 2006).  
 
It has also been suggested that only ATM mutations with specific functional 
consequences would predispose to breast cancer (Khanna & Chenevix-Trench 2004) and 
that dominant-negative mutations, missense changes in particular, which give rise to 
stable kinase-inactive or non-phosphorylable proteins, are the ones mainly responsible for 
the increased cancer risk in ATM mutation carriers (Gatti et al. 1999). The majority of 
ATM mutations found in A-T patients are truncating mutations, and this and the large size 
of the gene led to the fact that most of the first studies on ATM mutations in breast cancer 
patients used methods that are biased towards detecting protein truncating mutations. Yet, 
two recent studies in A-T families did not identify differences in cancer risk based on 
mutation type (Cavaciuti et al. 2004, Thompson et al. 2005), but it was suggested that the 
breast cancer risk in A-T families would be associated specifically with mutations located 
in the binding domains of the ATM protein (Cavaciuti et al. 2004).  
 
Recent studies have reported a significant prevalence of ATM mutations, especially of 
those causative for A-T, in breast cancer families (Thorstenson et al. 2003, Renwick et al. 
2006, Bernstein et al. 2006, see 6.1.1).  
2.4.6 Diseases associated with the MRN complex genes 
Hypomorphic biallelic NBS1 mutations cause the autosomal recessive condition, 
Nijmegen breakage syndrome (NBS) (Varon et al. 1998), a chromosomal instability 
syndrome characterized by microcephaly, growth retardation, immunodeficiency, and 
predisposition to cancer, particularly lymphomas. The phenotype of NBS patients shows 
significant overlap with A-T, and the cells from NBS patients are hypersensitive to 
ionizing radiation and have cytogenetic features indistinguishable from those of A-T. 
Biallelic MRE11 mutations cause ataxia-telangiectasia-like disorder (ATLD) which is 
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characterized by slowly progressive ataxia and ocular apraxia, the same clinical features 
as A-T but with later onset and slower progression (Stewart et al. 1999). Cells from 
ATLD patients show many of the features characteristic of both A-T and NBS, including 
chromosomal instability, increased sensitivity to ionizing radiation, defective induction of 
stress-activated signal transduction pathways, and radioresistant DNA synthesis. 
Mutations in RAD50 have not been associated with a defined human phenotype. 
However, a hypomorphic mutation of RAD50 has been identified in a patient suffering 
from a syndrome broadly reminiscent of NBS (Shiloh 2003).  
 
NBS1, and especially the Slavic founder mutation 657del5, has been associated with 
increased risk of prostate cancer (Cybulski et al. 2004c) and breast cancer (Gorski et al. 
2003, Steffen et al. 2004, 2006), but the reports have been inconsistent for both cancers 
(Hebbring et al. 2006, Buslov et al. 2005, Kanka et al. 2007). Other heterozygous NBS1 
alterations as well as certain NBS1 haplotypes have also been suggested to associate with 
breast cancer (Heikkinen et al. 2003, 2006, Lu et al. 2006) and childhood acute 
lymphoblastic leukemia (ALL) (Varon et al. 2001). Recently, a truncating RAD50 
mutation, 687delT, was reported to contribute to breast cancer in Northern Finland 
(Heikkinen et al. 2003, 2006).  
2.5 p53 
2.5.1 Structure and function 
p53 gene maps to chromosome 17p13 and comprises of 11 exons, first of which is non-
coding (Lamb & Crawford 1986). It encodes a 53 kD nuclear phosphoprotein with 
cancer-inhibiting properties. p53 is a transcription factor constitutively expressed in most 
cell types. It consists of an N-terminal transactivation domain, a central DNA-binding 
domain, a tetramerization domain and a C-terminal regulatory domain (Figure 5). The N-
terminal transactivation domain includes the proline-rich region suggested to be involved 
in the growth suppression and apoptosis inducing activities of p53 (Walker & Levine 









Figure 5. Structure of p53 (Adapted from Bai & Zhu 2006.). NLS, nuclear localization 
signal sequence; NES, nuclear export signal sequence. 
 
The p53 protein is a multi-functional transcription factor involved in the control of cell-
cycle progression, DNA integrity and apoptosis in cells exposed to DNA-damaging 
agents. The function of the p53 protein is regulated by several different biochemical 
modifications such as phosphorylation, acetylation and ubiquitination (reviewed in 
Lacroix et al. 2006).  
 
Many functions of p53, including its primary role in tumor suppression, can be attributed 
to its ability to act as a sequence-specific transcription factor which regulates expression 
of different cellular genes to modulate various cellular processes (Farmer et al. 1992). As 
a sequence-specific transcription factor it regulates expression of over hundred different 
target genes. Genes activated by p53 are functionally diverse; they are downstream 
effectors of signaling pathways that elicit diverse responses such as cell-cycle 
checkpoints, cell-cycle arrest, DNA repair, cell survival, apoptosis, and senescence 
(Vogelstein et al. 2000, Vousden & Lu 2002). In response to various types of stress, p53 
is accumulated in the nucleus and binds to specific sites in the regulatory regions of p53-
responsive genes strongly promoting the transcription of these genes (Kern et al. 1991).  
 
As a tumor suppressor, p53 is essential for preventing inappropriate cell proliferation and 
maintaining genome integrity following genotoxic stress (Vogelstein et al. 2000, 
Vousden & Lu 2002). Among various cellular stress responses induced by p53, most 
notable are the induction of cell-cycle arrest and apoptosis. p53 is involved in inducing 
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cell-cycle arrest in the G1/S, intra-S-phase, and G2/M checkpoints (see also 2.4.3). The 
induction of cell-cycle arrest at G1 and G2 by p53 provides additional time for the cell to 
repair genomic damage before entering the critical stages of DNA synthesis and mitosis. 
However, DNA-repair failure may result in the activation of apoptosis. As a cellular 
gatekeeper, one of the most important roles of p53 is to monitor cellular stress and to 
induce apoptosis when necessary (Levine 1997).  
 
p53 controls apoptosis both through inducing transcription of pro-apoptotic genes and 
repressing transcription of anti-apoptotic genes. The genes controlled by p53 can induce 
apoptosis through two main pathways, the intrinsic, mitochondrial pathway and the 
extrinsic, death receptor pathway (Chipuk & Green 2006). The mitochondrial pathway is 
induced by cellular stresses, such as DNA damage or hypoxia, and operates through the 
Bcl-2 family of pro- and anti-apoptotic proteins. Pro-apoptotic proteins of the Bcl-2 
family, such as Bax, Noxa, Puma, and p53AIP1 (Miyashita & Reed 1995, Oda E et al. 
2000, Nakano & Vousden 2001, Oda K et al. 2000) localize to the mitochondria and elicit 
the mitochondrial outer-membrane permeabilization (MOMP) (Spierings et al. 2005) and 
release of cytochrome c, resulting in the formation of the apoptosome complex with 
Apaf-1 (Moroni et al. 2001) and in the Apaf-1 dependent activation of caspase 9. Caspase 
9 in turn activates the executioner caspases 3 and 7. Caspases are cysteine proteases 
taking care of the apoptotic hallmarks, such as chromatin condensation, plasma 
membrane asymmetry, and clearance of the apoptotic cell. In the death receptor pathway, 
binding of death ligands to their death receptors on the plasma membrane, such as 
binding of the tumor necrosis factor (TNF) to its death receptor TNFR1, causes the 
recruitment of adaptor molecules (Muppidi et al. 2004) and activation of caspase 8, 
which again activates caspases 3 and 7, leading to cell death. p53 plays a role in death 
receptor induction and transport. It also directly binds anti-apoptotic and activates pro-
apoptotic Bcl-2 proteins to regulate MOMP (Chipuk & Green 2006).  
 
Due to its many functions in maintaining the genomic integrity, p53 has been named as 
“the guardian of the genome” (Lane 1992). Loss of p53 activity predisposes cells to the 
acquisition of oncogenic mutations and may favor genetic instability. p53 has been 
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considered as a classic tumor suppressor gene. The development of human cancer often 
involves inactivation of this suppressor function through various mechanisms. Most p53 
mutations disturb the transcriptional activity of p53, resulting in loss-of-function of its 
antiproliferative and apoptosis-inducing properties either through the complete loss of the 
wild-type p53 or through the dominant-negative effect of the mutated allele on the wild-
type allele. However, evidence is piling up that some mutations are gain-of-function 
mutations, leading to oncogenic functions, such as activation of other oncogenes or 
attenuation of other tumor suppressor genes (Ko & Prives 1996, Kastan & Berkovich 
2007). Recent data suggest that certain p53 mutants gain the ability to inhibit the MRN-
ATM signaling pathway involved in controlling cellular responses to DNA double-strand 
breaks and may this way contribute to tumor development through enhanced genomic 
instability (Song & Hollstein 2007).  
2.5.2 p53 in breast cancer 
Inherited mutations in p53 result in Li-Fraumeni syndrome and predispose to a wide 
spectrum of early-onset cancers, including breast cancer (see 2.3.1.1). In addition, 
somatic p53 alterations are frequent in most human cancers; p53 is the most frequently 
inactivated tumor suppressor gene in human cancer. The types of mutations observed in 
the germline and in sporadic cancer cases are in general similar. Unlike for instance 
BRCA1 and BRCA2, where most mutations are truncating, most of the mutations (over 
75%) in p53 are missense mutations, and 97% of them cluster in exons encoding the 
DNA-binding domain (Olivier et al. 2002).  
 
p53 mutations are found in 20-40% of all breast cancer tumors, depending on tumor size 
and stage of the disease, and mutation of p53 seems to be an early event in breast 
tumorigenesis (Børresen-Dale 2003). p53 mutations have been observed with higher 
frequency in breast cancer tumors of BRCA1 mutation carriers than in sporadic tumors; 
for BRCA2 the results have been less conclusive (Honrado et al. 2005). Some p53 
mutations found in the breast tumors of BRCA1/2 mutation carriers are infrequently 
reported in sporadic cancers, which may reflect the distinct selective pressures operating 
during tumorigenesis in BRCA1/2-associated breast cancers (Gasco et al. 2003).  
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Many studies have confirmed that mutated p53 is a strong independent prognostic factor 
in breast cancer. The risk of dying of breast cancer for patients with a p53 mutation in 
their tumor has been estimated to be two to five-fold compared to patients with wild-type 
p53 tumors (Pharoah et al. 1999 Olivier et al. 2006, Petitjean et al. 2007). The prognostic 
value of p53 accumulation in the tumor detected by immunohistochemistry has remained 
weaker in many studies, as correlation between p53 mutation status and p53 staining in 
the tumor is not very strong. Positive immunostaining for p53 is in general considered to 
indicate somatic p53 mutation and impaired p53 pathway, as most p53 alterations found 
in breast carcinomas are point mutations leading to the synthesis of a stable, 
malfunctional, and nondegradable protein that accumulates in tumor cells, and thus can 
be detected by immunohistochemistry. It is, however, shown that not even all the p53 
missense mutations cause increased expression of a p53 protein detectable by 
immunostaining, and mutations resulting in protein truncation are not detected by 
immunohistochemistry (reviewed in Børresen-Dale 2003). Approximately 30% of the 
p53 mutations detected by sequencing do not cause positive staining in the tumor 
(Sjögren et al. 1996, Norberg et al. 1998). p53 mutation status as a predictor of therapy 
response in breast cancer has also been under extensive investigation recently. Due to 
different clinical and methodological settings used, the results have been heterogeneous 
and even contradictory (Petitjean et al. 2007). Association of p53 mutation status with 
treatment outcome has been reported in a number of studies, and resistance to 
radiotherapy and different chemotherapeutic agents associated with certain specific types 
of p53 mutations has also been suggested (reviewed in Børresen-Dale 2003 and Lacroix 
et al. 2006). The predictive value of p53 mutations in breast cancer warrants further 
studies with larger numbers of cases.  
2.5.3 p53 R72P polymorphism 
Exon 4 of p53 harbors a common polymorphism, 215G>C. This base change results in an 
arginine to proline change in the protein sequence. There is a correlation between the 
frequency of 72P and latitude (from 17% in Swedish Saamis to 63% in African 
Nigerians), suggesting that 72P might have been selected for because of its protective 
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effect against high levels of ultraviolet radiation (Beckman et al. 1994). However, the 
human R72 allele is new on the evolutionary scale: the wild-type allele in mouse and 
chimpanzee is 72P. The R72P polymorphism is located in a proline-rich region of p53 
suggested to be required for the growth suppression activity of p53 (Walker & Levine 
1996) and for its ability to induce apoptosis (Sakamuro et al. 1997). These two variant 
protein forms, R72 and 72P, have been shown to differ in their biological functions. The 
R72 variant is a stronger and faster inducer of apoptosis than the 72P variant (Thomas et 
al. 1999, Pim & Banks 2004), which may at least in part be due to the enhanced 
localization of R72 variant to the mitochondria (Dumont et al. 2003). The 72P allele also 
enhances binding of iASPP, an inhibitor of pro-apoptotic function of p53 (Bergamaschi 
et al. 2003), to p53, which may be another reason for the inferiority in apoptosis 
induction of this allele (Bergamaschi et al. 2006). On the other hand, the 72P variant has 
been found to be more efficient in inducing cell-cycle arrest (Pim & Banks 2004) and 
DNA repair (Siddique & Sabapathy 2006) than the R72 variant.  
 
Because of the differences of these two alleles in important biological functions, such as 
induction of transcription and apoptosis, the role of R72P polymorphism in cancer has 
been investigated in a number of studies. The R72 variant is more susceptible than the 
72P variant to degradation induced by human papillomavirus (HPV) E6 protein, and this 
was suggested to result in an increased susceptibility to HPV-induced tumors in R72 
homozygous individuals (Storey et al. 1998). Some studies have reported an 
overrepresentation of the R72 variant in cervical cancers compared to control samples 
(Zehbe et al. 1991, 2002), whereas a larger meta-analysis study did not find such an 
association (Koushik et al. 2004).  
 
The studies on R72P and risk of other types of cancer, including breast cancer, have also 
yielded inconsistent, even contradictory results. Most studies have been small and the 
results have not been replicated in subsequent studies. The association of the 72P allele 
with lung cancer has been suggested in several studies (Wang et al. 1999, Fan et al. 2000, 
Mechanic et al. 2007). On the contrary, initially suggested association of 72P with 
prostate cancer has not been seen in more recent studies (Huang et al. 2004). The 72P 
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allele has also been suggested to play a role in colorectal cancer development (Koushik et 
al. 2006) and pathogenesis: HNPCC (Lynch syndrome) patients with MSH2 or MLH1 
germline mutations and carrying 72P were reported to develop colorectal cancer at a 
younger age than R72 homozygotes (Jones et al. 2004), while another study reported 
poorer survival among colorectal cancer patients with the 72P allele (Starinsky et al. 
2004), but at least the association with the age at onset has been challenged by other 
studies (Sotamaa et al. 2005, Talseth et al. 2006, 2007).  
 
After an initial report of increased breast cancer risk in women homozygous for 72P 
(Själander et al. 1996) the result was replicated in at least one study (Huang et al. 2003), 
but some other studies have reported increased risk in women homozygous for R72 
(Buyry et al. 2003, Ohayon et al. 2005). Studies that argue against the contribution of the 
R72P polymorphism in breast cancer predisposition have also been reported (Wang-
Gohrke et al. 2002, Suspitsin et al. 2003). Association of R72 homozygous genotype with 
multiple cancers, especially in BRCA1/2 mutation carrier breast cancer families, has also 
been suggested (Martin et al. 2003).  
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3 AIMS OF THE STUDY 
The aims of this study were 
 
1. to evaluate the contribution of the Finnish ataxia-telangiectasia (A-T) –mutations 
on breast cancer risk in Finnish breast cancer families (I) and to investigate 
whether other ATM sequence variants are contributing to breast cancer in 
Southern Finland (II) 
2. to study by immunohistochemistry the expression of the ATM gene in breast 
tumors (III) to explore its role in breast carcinogenesis 
3. to examine the contribution of RAD50 on familial breast cancer predisposition in 
Southern Finland and UK (IV) 
4. to evaluate the effect of p53 R72P polymorphism on breast cancer risk, 
histopathologic features of the tumors and survival of the patients (V) 
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4 MATERIALS AND METHODS 
4.1 Subjects 
4.1.1 Breast cancer families (I, II, IV, V) 
In study V, the series of familial breast cancer patients was genotyped for p53 R72P 
polymorphism to evaluate its association with breast cancer risk. The series included 
altogether 939 familial breast cancer patients collected at the Helsinki University Central 
Hospital Departments of Oncology, Clinical Genetics and Surgery (as described in Eerola 
et al. 2000). This series included 407 breast cancer patients with a stronger family history 
(three or more first- or second- degree relatives with breast or ovarian cancer in the 
family, including the proband), and 532 unrelated breast cancer cases reporting only a 
single affected first-degree relative. Among these 939 familial patients, 804 had a family 
history of breast cancer only and 135 patients had a relative affected with ovarian cancer. 
All cancer diagnoses were verified through the Finnish Cancer Registry or hospital 
records. For 627 of these familial patients, BRCA1 and BRCA2 mutations had been 
excluded. BRCA1/2 mutation screening was done either by screening of the entire coding 
regions and exon-intron boundaries using protein truncation test (PTT) and denaturing 
gradient gel electrophoresis (DGGE), or as previously described in Vehmanen at al. 
1997, Vahteristo et al. 2001 and Vahteristo et al. 2002. For 312 patients, the BRCA1/2 
mutation status was unknown.  
 
In study I, index cases of altogether 541 BRCA1 and BRCA2 mutation negative families 
from Helsinki, Tampere, and Oulu areas were screened for eight Finnish A-T-related 
ATM mutations. Inclusion criteria for the families were 1) three or more affected in the 
family (285 cases), 2) two affected first-degree relatives (251 cases) or 3) two affected 
second-degree relatives (5 cases). Two hundred and two of the cases from families with 
three or more affected and 172 of the cases from families with two affected first-degree 
relatives belonged to the familial series from Helsinki described above.  
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In study II, forty-seven BRCA1/2 mutation negative breast cancer patients with the 
above-mentioned stronger family history from the familial series were screened for 
germline alterations in the ATM gene. The five rare ATM variants found in the first screen 
were then screened in additional 237 BRCA1/2 mutation negative breast cancer patients 
with the stronger family history. The rare missense variant ATMex10 998C>T (S333F) 
was also screened in additional 368 breast cancer cases with moderate family history.  
 
In study IV, 590 Finnish breast cancer patients were screened for RAD50 687delT 
mutation. The patients belong to the series of familial breast cancer patients described 
above and are described in detail in IV. Of these patients, 281 were also screened for 
RAD50 Q350X. Altogether 46 Finnish breast cancer patients were screened for the whole 
RAD50 gene. They were from BRCA1/2 negative families with three or more affected 
cases. The 702 BRCA1/2 mutation negative UK patients screened for RAD50 mutations 
in study IV were collected through the Breast Cancer Susceptibility Collaboration (UK) 
and are described in detail in IV.  
 
In study V, the p53 R72P polymorphism was evaluated also in 49 BRCA1 and 48 BRCA2 
mutation carriers affected with breast cancer to investigate whether this polymorphism 
modifies cancer risk in BRCA1 or BRCA2 mutation carriers.  
4.1.2 Unselected breast cancer patients (I, II, V) 
Unselected breast cancer patients were genotyped for the common polymorphisms 
ATMivs38 -8T>C, ATMex39 5557G>A (D1853N) (II) and p53 R72P (IV) to evaluate the 
association of the polymorphisms with breast cancer risk as well as histopathologic 
features of the breast tumors and survival of the patients. The series of 888 unselected 
breast cancer patients included 626 consecutive newly diagnosed breast cancer patients 
collected 1997 - 1998 at the Helsinki University Central Hospital covering 87% of all 
breast cancer patients treated at the Department of Oncology during the collection period 
(described in detail in Syrjäkoski et al. 2000). Additionally, the series included samples 
collected from 262 consecutive newly diagnosed breast cancer patients at the Department 
of Oncology, Helsinki University Central Hospital, in 2000, covering 65% of all breast 
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cancer patients treated at the Department of Oncology at that time period (Kilpivaara et 
al. 2005).  
 
Pathologic data were collected from pathology reports for all the primary breast tumors 
available among the 888 unselected breast cancer patients. Altogether, 46 bilateral breast 
cancer cases had been diagnosed among these 888 patients with histopathologic data 
available for a total of 932 tumors (932/934, 99.8% of all). The data set included 
information on tumor histology, grade, estrogen receptor (ER) and progesterone receptor 
(PR) status, p53 immunohistochemical expression and tumor diameter (T), nodal status 
(N), and distant metastases (M). The data set for the unselected patients collected 1997 - 
1998 also included the age at the time of (first) breast cancer diagnosis and survival 
(follow-up in months).  
 
In study I, the frequencies of the Finnish A-T-related ATM mutations observed in familial 
breast cancer patients were compared to those in geographically matched 1124 unselected 
breast cancer cases and 1107 healthy controls; 450 unselected breast cancer patients 
belonged to the series of 626 unselected patients from Helsinki collected 1997 - 1998.  
4.1.3 Population controls (I, II, IV, V) 
In study I, DNA from the 1107 healthy blood donors from matched geographical regions 
was obtained from the Finnish Red Cross Blood Service. The samples belong to the 
series collected at eight regional centers around the country covering all the geographical 
regions in Finland.  
 
In studies II, IV and V, peripheral blood from the healthy blood donors from Southern 
Finland was obtained from the Finnish Red Cross Blood Service. The samples belong to 
the series of 1344 samples collected in 2003.  
 
Samples from the 786 UK controls in study IV were obtained from Human Random 
Control DNA panels from the European Collection of Cell Cultures (Salisbury, UK).  
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4.1.4 Tumor arrays (III, V) 
Paraffin-embedded tissue blocks of the available primary breast cancer tumors from 
unselected breast cancer patients (III, V) and familial breast cancer patients (III) as well 
as pathologic data from pathology reports including information on tumor histology, 
grade, estrogen receptor (ER) and progesterone receptor (PR) status and tumor diameter, 
nodal status, and distant metastases were collected. All tumors were additionally re-
reviewed for histological grade and histological tumor type by one pathologist (P.H.). 
Grading was performed according to Scarff-Bloom-Richardson modified by Elston and 
Ellis (1991). The most representative area of the tumors was punched to produce breast 
cancer tissue microarrays (TMA) including four cores (diameter 0.6mm) from each of the 
original blocks.  
 
The TMAs included altogether 1335 invasive breast cancer tumors: 921 of these were 
from familial patients (577 from families with three or more first- or second- degree 
relatives with breast or ovarian cancer, including the proband, and 344 from families with 
two affected first-degree relatives) and 414 from sporadic patients (patients without the 
above defined family history of breast or ovarian cancer). Fifty-two of the tumors from 
familial patients were from patients from BRCA1 mutation positive families and 56 
tumors were from patients from BRCA2 mutation positive families. Altogether 655 
familial tumors were from families for which BRCA1 and BRCA2 mutations had been 
excluded (including all cases with strong family history) and 158 tumors were from 
families for which the BRCA1 and BRCA2 mutation status was unknown (families with 
two affected cases). Altogether 134 patients had bilateral breast cancer; both tumors were 
available of 38 patients.  
4.1.5 Cell lines (I, IV) 
The cell lines used in the functional studies of the Finnish A-T-mutations (I) are 
described in I.  
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In study IV, lymphoblast cell lines were established from three heterozygous carriers of 
the RAD50 687delT mutation, and from one non-carrier, by Epstein-Barr virus (EBV) 
transformation.  
4.2 DNA and RNA extraction, cDNA synthesis (I, II, IV, V) 
Genomic DNA from peripheral blood lymphocytes was extracted by a standard phenol-
chloroform method (I, II, IV, V). Total cellular RNA from lymphoblast cell lines was 
extracted by a standard Trizol (Invitrogen) method followed by purification with RNeasy 
mini-kit (Qiagen), and cDNA was synthesized using R-T-PCR System with random 
hexamer primers (Promega) (unpublished). Genomic DNA from frozen tumor tissue was 
obtained when RNA from the tissue was extracted by Trizol method (IV).  
4.3 Mutation analysis and genotyping (I, II, IV, V) 
4.3.1 Search for novel mutations (II, IV) 
4.3.1.1 Denaturing high-performance liquid chromatography (dHPLC) (II) 
Genomic DNA from the index patients from forty-seven BRCA1/2 mutation negative 
breast cancer or breast-ovarian cancer families (three or more first or second degree 
relatives with breast or ovarian cancer in the family, including the proband) was screened 
for germline alterations in all coding exons and exon-intron boundaries of the ATM gene 
by denaturating high-performance liquid chromatography (dHPLC, WAVE, 
Transgenomic Inc., Omaha, NE, USA). The WECARE primers (described in Bernstein et 
al. 2003) were used for PCR amplification of genomic DNA. dHPLC was also used to 
screen the additional 237 familial nonBRCA1/2 breast cancer patients and 237 healthy 
population controls for the five rare ATM variants found in the first screen.  
4.3.1.2 Conformation sensitive gel electrophoresis (CSGE) (IV) 
All coding exons and exon-intron boundaries of the RAD50 gene (IV) from index patients 
from forty-six BRCA1/2 mutation negative Finnish breast cancer families were screened 
for mutations by conformation sensitive gel electrophoresis (CSGE) (Ganguly 2002). 
Briefly, genomic DNA was amplified by PCR and the PCR products denatured at +95°C 
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for 10 min, after which the PCR machine was switched off to allow the products to 
slowly cool to RT (45 min) and form heteroduplexes. Samples were run on mildly 
denaturing gels (10% acrylamide, 10% ethylene glycol, 15% formamide) at 3 W over 
night. The result was visualized by silver staining. CSGE was also used to screen the rare 
Finnish A-T-mutations in the breast cancer patients and population controls from 
Northern Finland in study I.  
4.3.2 Screening of the known mutations and genotyping common 
polymorphisms (I, II, IV, V) 
4.3.2.1 Agarose gel electrophoresis (I) 
ATMex62 8710-8715delGAGACA mutation in patients from Southern Finland was 
screened by running the PCR products in 3.5% ethidium bromide –stained MetaPhor® 
agarose gel (Cambrex Biosciences) and visualizing them under UV light.  
4.3.2.2 Minisequencing (primer extension) (I, II, IV) 
Minisequencing (primer extension, Syvänen et al. 1993) was used to screen the Finnish 
A-T-mutations in familial breast cancer patients from Southern Finland (except for 
ATMex62 8710-8715delGAGACA mutation screened by direct agarose gel 
electrophoresis, I) and the two truncating RAD50 mutations in Finnish familial breast 
cancer patients and healthy controls (IV). Genotyping the additional 237 familial 
nonBRCA1/2 breast cancer patients for the ATMex39 5557G>A (D1853N) polymorphism 
(II) was also done by minisequencing.  
4.3.2.3 Restriction fragment length polymorphism (RFLP) analysis (II) 
The ATMivs38 -8T>C polymorphism was genotyped by RFLP. RFLP was also used to 
screen the rare missense variant ATMex10 998C>T (S333F) in additional 368 breast 
cancer cases with moderate family history and 367 healthy controls. The ATMivs38 -
8T>C change creates a restriction site for RsaI; for ATMex10 a mutagenesis PCR-primer 
was designed that creates a restriction site for EcoRI, which is abolished by the 998C>T 
change. In brief, genomic DNA was amplified by PCR and carriers of the ATMivs38 -
8T>C or ATMex10 998C>T change could be detected in a 2% or 3% ethidium bromide –
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stained agarose gel after RsaI or EcoRI (New England BioLabs, Beverly, MA, USA) 
digestion of the PCR-products, respectively.  
4.3.2.4 Amplifluor™ fluorescent genotyping (II, V) 
ATMex39 5557G>A (D1853N) polymorphism (II, unselected breast cancer patients, 
breast cancer patients with moderate family history and population controls) and p53 
R72P polymorphism (V) were genotyped by using Amplifluor™ fluorescent genotyping 
(K-Biosciences, Cambridge, UK, http://www.kbioscience.co.uk).  
4.3.2.5 Direct sequencing (I, II, IV) 
Direct sequencing was used to characterize the new sequence alterations found with 
dHPLC (II) and CSGE (IV), and to confirm the positive results obtained when screening 
known rare alterations by dHPLC (II), CSGE (I), minisequencing (I, IV), and RFLP (II). 
Genomic DNA was first re-amplified and the PCR products purified with the QIAquick 
PCR purification kit (Qiagen) or with ExoSAP-IT treatment (Amersham Biosciences, 
Piscataway, NJ, USA). The purified PCR products were then bidirectionally sequenced 
using the ABI BigDyeTerminator Cycle Sequencing Kit (v3.0) and ABI Prism 310 
Genetic Analyzer automated sequencer (Applied Biosystems, Foster City, CA, USA). 
The RAD50 Q350X mutation was analysed in 267 additional UK familial breast cancer 
patient samples and 786 population controls by bidirectional sequencing of RAD50 exon 
7 (IV).  
 
Expression of the mutant and wild-type RAD50 alleles (unpublished) was evaluated by 
direct sequencing of cDNA generated from three lymphoblast cell lines established from 
heterozygous carriers of the 687delT mutation. PCR primers were designed in exons 5 
and 7 to avoid amplification of residual genomic DNA. The presence of ATM 6903insA 
transcript in the mRNA pool of mutation carrier cell lines was also evaluated by direct 
sequencing with cDNA-specific primers as described in I.  
 
Genomic DNA from tumor tissue from one RAD50 687delT mutation carrier was 
sequenced and compared to a non-carrier in order to study possible allelic imbalance (AI) 
(IV).  
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4.3.2.6 Microsatellite marker analysis (I) 
D11S1819, D11S2179, D11S1778, D11S1294 and D11S1818 markers were used to 
determine the haplotypes of observed ATM mutation alleles in study I, and to study 
possible allelic imbalance (AI) in the tumors of one 6903insA and two 7570G>C carriers. 
The PCR products were analyzed with the Li-Cor IR2 4200-S DNA Analysis system (Li-
Cor Inc., Lincoln, NE) using an IRD800-labelled forward primer. Allele intensity ratios 
were quantified with the Gene Profiler 4.05 analysis program (Scanalytics, Inc., Fairfax, 
VA). AI was calculated from the formula AI = (T2 x N1)/(T1 x N2), where T1/2 
represents tumor and N1/2 the corresponding normal alleles. A value >1.67 or <0.60 was 
considered to indicate AI, meaning that the intensity of one allele had decreased >40%.  
4.4 Functional studies and protein expression studies (I, III, 
IV, V) 
4.4.1 Cell survival studies (I) 
In order to study the effect of the three ATM mutations on radiosensitivity, the cell 
survival of mutation carrier and control cell lines after exposure to ionizing radiation was 
evaluated by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
assay, as described in detail in I. Cell survival fraction was calculated relative to the 
number of viable cells in the non-irradiated culture at 96 hours.  
4.4.2 Protein expression and kinase activity studies by immunoblotting 
(I, IV) 
The effects of the three ATM mutations on ATM expression and kinase activity (I) were 
evaluated by western blotting analysis as described in detail in I. Briefly, ATM was 
immunoprecipitated from cellular extracts of the carrier and control cell lines with anti-
ATM polyclonal antibody and the immunoprecipitates were resolved on SDS-PAGE gels 
and immunoblotted with the same antibody. To study ATM kinase activity, the 
phosphorylation of two ATM substrates, p53 (Ser15) and CHEK1 (Ser317), as well as 
ATM autophosphorylation on Ser1981 was evaluated before and after ionizing radiation: 
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extracts from mock or irradiated cells were analyzed by SDS-PAGE and immunoblotted 
with appropriate antibody.  
 
The RAD50 protein expression (IV) was evaluated by immunoblotting on cell lysates 
from three lymphoblast cell lines established from patients heterozygous for 687delT 
mutation, compared to a control lymphoblast cell line homozygous for wild-type RAD50. 
For immunoblotting analysis, proteins from total cell lysates were separated using 
denaturing polyacrylamide gel electrophoresis (10% SDS-PAGE) and blotted onto 
nitrocellulose membrane. The RAD50 protein was visualized on parallel blots after 
incubation with three distinct primary antibodies (ab3622 from Abcam, Cambridge, UK, 
clone 13 from Transduction Laboratories, Lexington, KY, USA and 13B3 from GeneTex, 
Inc., San Antonio, TX, USA) using the ECL visualization reagents (Amersham 
Biosciences, Piscataway, NJ, USA).  
4.4.3 Immunohistochemical analyses (III, IV, V) 
4.4.3.1 p53 (III, V) 
p53 protein expression on breast tumors (III, V) was studied by immunohistochemical 
staining of tumor tissue microarrays (TMA). The TMA slides were stained with a mouse 
monoclonal anti-human p53-antibody (Dako, Glostrup, Denmark) in a dilution of 1:300. 
Briefly, five-micron sections were cut from paraffin-embedded blocks, deparaffinized in 
xylene, and dehydrated in a series of graded alcohols. The sections were pre-treated in a 
microwave oven and incubated with antibody overnight. Samples were considered 
positive when 20% of the cancer cells were positive for the p53 staining.  
4.4.3.2 ATM (III) 
For ATM immunohistochemistry (III), the TMA slides were deparaffinized and 
processed for sensitive immunoperoxidase staining with the primary mouse monoclonal 
antibody against human ATM (ATML2p, recognizing an epitope between amino acids 
2581 and 2599 of ATM, obtained from Dr. Yosef Shiloh, described in Angèle et al. 2000, 
1:1000 dilution), incubated overnight, followed by detection using the Vectastain Elite kit 
(Vector Laboratories, Burlingame, CA, USA), as previously described (Lukas et al. 2001, 
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Vahteristo et al. 2002, Angèle et al. 2003, Bartkova et al. 2005a, 2005b). As more than 
90% of epithelial cells in the normal breast tissues (n=15) were positive for the ATM 
protein, ATM expression was considered aberrantly reduced when fewer than 70% of 
breast cancer cells were ATM-positive in a given tumor. ATM was also regarded as 
aberrantly reduced when the staining intensity of the breast cancer cells was clearly lower 
compared with the ATM staining signal in adjacent normal stromal, epithelial and/or 
lymphocytic infiltrating cells on the same section. The results were scored as follows: 1 = 
reduced intensity of staining of carcinoma cells, 2 = reduced number of carcinoma cells 
with positive staining, 3 = reduced intensity of staining of carcinoma cells and reduced 
number of carcinoma cells with positive staining, 4 = normal staining of carcinoma cells.  
4.4.3.3 ERBB2 (III) 
ERBB2 (HER2) protein expression (III) on tumors on TMAs was analyzed by 
immunohistochemical (IHC) staining and ERBB2 gene amplification with chromogenic 
in situ hybridization (CISH), as previously described (Tanner et al. 2000, Lassus et al. 
2004). The ERBB2 amplification was considered negative with 2-5 copies of ERBB2 in 
single nucleus and positive with >6-10 copies. When CISH result was not available, 
unambiguous IHC result (weak/negative staining or strong positivity >90% of cells) was 
used.  
4.4.3.4 RAD50, MRE11, and NBS1 (IV) 
The RAD50 protein expression was studied by immunohistochemical staining in three 
archival breast tumors from three patients heterozygous for 687delT mutation, compared 
to a series of normal breast tissues (n=15), familial breast carcinomas with apparently 
wild-type RAD50 (n=25) and sporadic breast tumors (n=27). The tumor sections were 
deparaffinized and processed for sensitive immunoperoxidase staining with the primary 
mouse monoclonal antibody against human RAD50 (clone 2C6, Abcam, Cambridge, UK, 
1:500 dilution), incubated overnight, followed by detection using the Vectastain Elite kit 
(Vector Laboratories, Burlingame, CA, USA), as previously described (Lukas et al. 
2001). Given that around 95% of epithelial cells were reproducibly and strongly positive 
on sections of normal breast, expression was regarded aberrantly decreased when the 
RAD50 protein was detectable in fewer than 70% of cancer cells in a particular lesion, 
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and the staining intensity of the remaining positive cancer cells was reduced compared to 
that in normal cells present on the same section. For analyses of the MRE11 and NBS1 
proteins on parallel sections, rabbit antibodies #4895 against MRE11 (Cell Signaling, 
diluted 1:1500) and #3002 against NBS1 (Cell Signaling, diluted 1:100) were used, 
respectively.  
4.5 Statistical and bioinformatic analyses (I, II, III, IV, V) 
4.5.1 Tests for statistical significance (I, II, III, IV, V) 
Fisher’s exact test or chi-square test was used to determine statistical significance (SPSS 
v12.0.1 for Windows, SPSS Inc., Chicago, IL, USA or Simple Interactive Statistical 
Analysis, SISA, http://home.clara.net/sisa/). All p-values are two-sided, and p<0.05 or 
p<0.01 (due to multiple testing) was considered significant.  
4.5.2 Odds ratios (I, II, III, IV, V) 
Odds ratios with 95% confidence intervals were calculated using Simple Interactive 
Statistical Analysis, SISA (http://home.clara.net/sisa/).  
4.5.3 Survival analyses (V) 
Univariate analyses of survival were performed by calculating Kaplan-Meier survival 
curves and comparing subsets of patients using log-rank test. To explore the effects of 
several variables on survival, Cox’s proportional-hazards regression model was used. The 
data were analyzed using SPSS v12.0.1 for Windows (SPSS Inc., Chicago, IL, USA).  
4.5.4 SIFT and PolyPhen analyses (II, IV) 
SIFT analysis (Ng & Henikoff 2002) (http://blocks.fhcrc.org/sift/SIFT) and PolyPhen 
(Ramensky et al. 2002) (http://genetics.bwh.harvard.edu/pph/) were used to evaluate 
functional significance of the missense variants found. SIFT program calculates tolerance 
scores for amino acid changes based on sequence alignment and conservation across 
protein family or across evolutionary history. PolyPhen (=Polymorphism Phenotyping) 
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predicts possible impact of an amino acid substitution on the structure and function of a 
human protein using straightforward physical and comparative considerations.  
4.5.5 Haplotype reconstruction (I, II) 
In study I, haplotypes were reconstructed manually. In II, haplotypes were reconstructed 
using PHASE (version 2.1.1) (http://www.stat.washington.edu/stephens/software.html). 
The software implements a Bayesian statistical method for reconstructing haplotypes 
based on population genotype data (Stephens et al. 2001, Stephens & Donnelly 2003).  
4.6 Ethical issues 
This study was performed with informed consents from the patients as well as with 
permissions from the Ethics Committee (E8) of the Helsinki University Central Hospital 
and from the Ministry of Social Affairs and Health in Finland.  
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5 RESULTS 
5.1 ATM and breast cancer (I, II, III) 
5.1.1 ATM sequence variants and breast cancer risk Finland (I, II) 
5.1.1.1 Finnish A-T mutations in breast cancer families (I) 
The presence of seven Finnish A-T –related ATM mutations was analyzed in 541 breast 
cancer families: only two mutations, 6903insA and 7570G>C, were observed in these 
families (Table 1). Additionally, another mutation, 8734A>G in exon 62, was identified. 
ATMex49 6903insA was observed in the index patients of three families. However, it 
showed incomplete segregation with cancer in the family where additional family 
members were available for analysis. ATMex49 6903insA was also found in 5/1124 
unselected breast cancer cases. All the eight mutation carriers originated from the 
Tampere region and shared the same haplotype (data not shown). ATMex53 7570G>C 
was found in one familial breast cancer patient from the Helsinki series (maternally 
originating from central Finland and paternally from Eastern Finland), also a carrier of 
CHEK2 1100delC mutation, and in 2/1124 unselected breast cancer patients from the 
Oulu region. This mutation was also observed in one healthy control (1/1107). All 
carriers of the mutation shared the same haplotype (data not shown). When screening the 
Finnish A-T-mutation, 8710-8715delGAGACA in ATM exon 62, with CSGE, another 
alteration, 8734A>G, previously related with breast cancer and A-T (Teraoka et al. 2001, 
Thorstenson et al. 2003), was observed and included in the study. ATMex62 8734A>G 
was found in index patients of two breast cancer families originating from the Tampere 
region. Both patients shared the same haplotype (data not shown). However, the 
segregation of the mutation with cancer was incomplete. ATMex62 8734A>G was not 
found in unselected breast cancer cases or in controls.  
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Table 1. Heterozygous ATM germline mutations in Finnish breast cancer families, unselected 
breast cancer cases and controls. 
ATM mutation                                            Carrier Frequency (%)  
Familial cases                      Unselected cases                Controls 
6903insA 0.6% (3/541) 0.4% (5/1124) - (0/1107) 
7570G>C 0.2% (1/541) 0.2% (2/1124) 0.1% (1/1107) 
8734A>G 0.4% (2/541) - (0/1124) - (0/1107) 
altogether 1.1% (6/541), p=0.006 0.6% (7/1124), p=0.07 0.1% (1/1107) 
In addition, the following Finnish A-T mutations were screened in familial cases: IVS14+3-4delAT (exon 14 
skipped), IVS37+9A>G (insertion Val, Ser, Stop), 6779-6780delTA (truncation), 8710-8715delGAGACA 
(deletion of Glu and Thr) and 9139C>T (Arg3047Stop). None of these mutations was found.   
5.1.1.2 Functional analyses of breast cancer –related A-T mutations (I) 
AI analysis was performed on available tumor samples of one 6903insA, and two 
7570G>C carriers. None of the tumors showed loss of the wild-type allele (data not 
shown). ATM expression analysis by western blotting showed that the amount of ATM 
protein from the 7570G>G and 8734A>G missense mutation carrier cell lines was 
normal. For 6903insA, leading to premature translation stop at codon 2372, no truncated 
protein was observed, but the level of full-length ATM protein expression was reduced to 
half. However, direct sequencing of the cDNA generated from the carrier cell lines 
showed that 6903insA transcripts were still present in the mRNA pool, indicating that 
they were not eliminated from the cells by nonsense-mediated decay (NMD). ATM 
kinase activity analysis by evaluating the phosphorylation of two ATM substrates, p53 on 
Ser15 and CHEK1 on Ser317, and ATM autophosphorylation on Ser1981 before and 
after IR revealed that DNA damage –induced phosphorylation of p53 and CHEK1 as well 
as ATM autophosphorylation was dramatically lower in the 7570G>C carrier cell line; 
the 8734A>G carrier cell line was defective only in CHEK1 phosphorylation. For 
6903insA, no difference between the carrier cell lines and controls was found, which 
indicates that the checkpoint signaling downstream of ATM is not compromised in 
6903insA carrier cell lines. Radiosensitivity analysis evaluating cell survival after 
exposure to IR showed that the survival of the 7570G>C and 8734A>G carrier cell lines 
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was similar to controls, whereas the survival of the 6903insA carrier cell lines was 
indistinguishable from that of A-T cell lines.  
5.1.1.3 Other ATM sequence variants in breast cancer patients from Southern 
Finland (II) 
As only one of the Finnish A-T mutations, ATMex53 7570G>C, was found in one 
familial breast cancer patient from the Helsinki series, we screened the whole coding 
region and exon-intron boundaries of the ATM gene in 47 familial breast cancer patients 
to see whether there are any other ATM sequence variants contributing to breast cancer in 
Southern Finland. ATM sequence variants found in the full gene screen from 47 Finnish 
familial breast cancer patients as well as haplotypes constructed with PHASE software 
are presented in Table 2.  
 
Table 2. ATM sequence variants and haplotypes found in 47 Finnish familial breast 
cancer patients. 
variant ex5 ex9 ex10 ex11 ex14 ex15 ex20 ex31 ex32 ex39a ex39b ex39c ex40 ex41 ex46 ex47 ex62
freq. 1/47 5/47 1/47 1/47 1/47 1/47 1/47 1/47 1/47 1/47 4/47 18/47* 1/47 1/47 2/47 1/47 2/47
freq. haplotype
0.65 1 T C C T A T - A C G T G G T T G A
0.01 2 T C C T A T - A C G T G G T T G C
0.01 3 T C C T A T - A C G T G G T T T A
0.02 4 T C C T A T - A C G T G G T C G A
0.01 5 T C C T A T - A C G T G A T T G C
0.01 6 T C C T A T - A C C T G G T T G A
0.15 7 T C C T A T - A C G T A G T T G A
0.02 8 T C C T A T - A C G C A G T T G A
0.01 9 T C C T A T - A T G C A G T T G A
0.01 10 T C C T A T - G C G T A G T T G A
0.01 11 T C C T G T - A C G T G G T T G A
0.01 12 T C C G A T - A C G T A G T T G A
0.01 13 T C T T A T - A C G C A G T T G A
0.01 14 T T C T A T A A C G T G G C T G A
0.03 15 T T C T A T - A C G T G G T T G A
0.01 16 T T C T A C - A C G T G G T T G A
0.01 17 C C C T A T - A C G T G G T T G A
* two homozygotes

















ex62 ivs 62(+8)A>C -  
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Altogether 17 different sequence variants forming 17 different haplotypes were found. 
Seven of the variants were intronic, four were silent nucleotide substitutions and six were 
missense changes. Four rare missense alterations and one of the intronic changes (Table 
3), ATMivs10 -6T>G, a known A-T-mutation leading to skipping of the exon eleven in 
the transcript (Dörk et al. 2001), were then screened in additional series of familial 237 
breast cancer cases and 237 healthy controls. As ATMex10 998C>T (S333F) missense 
variant was in this screen found more frequently in cases than in controls, it was further 
studied in additional 368 breast cancer cases with a moderate family history, and in 367 
healthy controls. The frequencies of these five variants in breast cancer cases and healthy 
controls are presented in Table 3.  
 
Table 3. Frequencies of five ATM variants in Finnish breast cancer cases and controls. 
ATM  variant cases controls SIFT PolyPhen
ex10 6/652 5/604




1814A>G (H605R) 0.40% 0.00% 0.00 possibly damaging
ex31 1/273 0/234
4424A>G (Y1475C) 0.37% 0.00% 0.08 probably damaging
ex47 1/264 0/234
6539G>T (G2180V) 0.38% 0.00% 0.03 probably damaging  
 
None of the variants segregated with cancer in the families studied. Only the index case 
with 998C>T (S333F) carried the variant in one family studied, with three other affected 
sisters being non-carriers; for two other families no additional samples were available. 
Similarly, only the index cases carried the ATMex14 1814A>G (H605R) and ivs10-6T>G 
variants. For 1814A>G, three other affected relatives (sister, cousin and her daughter) 
were not carriers. For the ivs10-6T>G variant, the two other affected in the family were 
not carriers whereas two of the three healthy sisters (aged 63 and 73 years) of the index 
case carried the variant. Unfortunately, no samples of affected relatives were available for 
the ATMex31 4424A>G (Y1457C) and ATMex47 6539G>T (G2180V) variant carrier 
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cases. The fifth rare missense alteration, ATMex15 2119T>C (S707P), was not studied 
further as it has been extensively studied previously, and the results do not support its 
association with breast cancer (Dörk et al. 2001, Spurdle et al. 2002, Sommer et al. 2003, 
Bretsky et al. 2003).  
 
Unselected and familial breast cancer patients as well as healthy controls were genotyped 
for the common polymorphisms ATMivs38 -8T>C and ATMex39 5557G>A (D1853N) to 
evaluate the association of the polymorphisms with breast cancer risk, bilateral breast 
cancer, multiple cancers, and the age of breast cancer diagnosis as well as with 
histopathologic features of the breast tumors and survival of the patients. The genotype 
distribution of the common ATMex39 5557G>A (D1853N) polymorphism was closely 
similar in breast cancer cases and healthy controls, suggesting no effect on breast cancer 
risk. No association of this polymorphism with bilateral breast cancer or multiple cancers 
(breast cancer and at least one other non-breast cancer) was seen among the familial or 
unselected breast cancer cases. No association with histopathologic features (tumor 
histology, grade, hormone receptor status, TNM stage) of the breast tumors or survival 
among the unselected breast cancer patients was seen, either (data not shown). This 
alteration also appeared well tolerated in SIFT (score 0.17) and PolyPhen (benign) 
analysis.  
 
No significant effect on breast cancer risk of the ATMivs38 -8T>C polymorphism (or the 
combined variant, as all the carriers of ivs38-8T>C also carried 5557G>A) was observed. 
It was not associated with any histopathologic features of the breast tumors or survival 
among the unselected breast cancer patients (data not shown). The ivs38-8T>C 
polymorphism was not significantly associated with the risk of bilateral breast cancer 
among unselected or familial breast cancer patients. Among the unselected breast cancer 
patients, the ivs38-8T>C polymorphism tended to be associated with an increased risk of 
multiple primary cancers (breast cancer and at least one other non-breast cancer) (OR 
2.56, 95% CI 1.23-5.35, p=0.02, Fisher’s exact test), but the result was only of borderline 
significance and was not seen among the familial cases.  
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5.1.2 ATM expression in breast cancer tumors (III) 
ATM staining was successful in altogether 1182/1335 (88.5%) tumors on TMAs. 
Altogether, the ATM protein expression was reduced in 10.7% of all nonBRCA1/2 breast 
cancer tumors. Proportion of tumors with reduced expression was similar among the 
tumors from familial and sporadic patients (Table 4). However, tumors from patients 
from BRCA1 and BRCA2 mutation positive families showed significantly more often 
reduced ATM expression than tumors from nonBRCA1/2 patients; 33.3% of BRCA1 
tumors and 30.0% of BRCA2 tumors showed reduced expression, p=0.0003 and p=0.0009 
as compared to nonBRCA1/2 tumors, respectively.  
 
Table 4. ATM expression in breast cancer tumors. 
ATM expression
total (%)
all nonBRCA1/2  tumors 1106 (100) 988 (89.3) 72 (6.5) 21 (1.9) 25 (2.3)
   sporadic 366 (100) 326 (89.1) 22 (6.0) 12 (3.3) 6 (1.6)
   familial 740 (100) 662 (89.5) 50 (6.8) 9 (1.2) 19 (2.6)
      three or more affected in the family 428 (100) 382 (89.3) 29 (6.8) 6 (1.4) 11 (2.6)
      two affected first-degree relatives in the family 312 (100) 280 (89.7) 21 (6.7) 3 (1.0) 8 (2.6)
BRCA1  tumors 36 (100) 24 (66.7) 9 (25.0) 1 (2.8) 2 (5.6)
BRCA2  tumors 40 (100) 28 (70.0) 11 (27.5) 0 (0.0) 1 (2.5)
*reduced intensity of staining of carcinoma cells
**reduced number of carcinoma cells with positive staining
***reduced intensity of staining of carcinoma cells and reduced number of carcinoma cells with positive staining
normal 1* 2** 3***
 
 
Histopathologic features of nonBRCA1/2 tumors with normal and aberrant ATM protein 
expression are shown in Table 5. The tumors with reduced ATM expression were 
significantly more often ER negative (p=0.0002), PR negative (p=0.004) and of higher 
grade (p=0.0004, grade 3 vs. 1+2) than the tumors with normal ATM expression. The 
tumors with reduced ATM expression were also more often of medullary histology than 
the tumors with normal ATM expression (p=0.01). For other parameters studied (TNM 




Table 5. Histopathologic features of nonBRCA1/2 breast cancer tumors with normal and 
aberrant ATM expression. 
Total (%) normal aberrant p*
Tumor histology (n=1106)
 Ductal carcinoma 798 (72.2) 705 (71.4) 93 (78.8)
 Lobular carcinoma 188 (17.0) 173 (17.5) 15 (12.7)
 Medullary carcinoma 14 (1.3) 9 (0.9) 5 (4.2) 0.01
 Other 106 (9.6) 101 (10.2) 5 (4.2)
Grade (n=1097)
1 251 (22.9) 238 (24.3) 13 (11.1)
2 509 (46.4) 458 (46.7) 51 (43.6)
3 337 (30.7) 284 (29.0) 53 (45.3) 0.0004
T (n=1092)
1 641 (58.7) 582 (59.7) 59 (50.4)
2+3+4 451 (41.3) 393 (40.3) 58 (49.6) 0.06
N (n=1089)
negative (0) 597 (54.8) 539 (55.3) 58 (50.4)
positive (1+2) 492 (45.2) 435 (44.7) 57 (49.6) 0.3
M (n=1068)
negative 1032 (96.6) 927 (97.0) 105 (93.8)
positive 36 (3.4) 29 (3.0) 7 (6.3) 0.09
ER status (n=1055)
negative 217 (20.6) 177 (18.8) 40 (34.8) 0.0002
positive 838 (79.4) 763 (81.2) 75 (65.2)
PR status (n=1052)
negative 349 (33.2) 297 (31.7) 52 (45.2) 0.004
positive 703 (66.8) 640 (68.3) 63 (54.8)
ERBB2 (n=1066)
negative 926 (86.9) 826 (87.0) 100 (85.5) 0.7
positive 140 (13.1) 123 (13.0) 17 (14.5)
ER/PR/ERBB2 (n=1013)
negative for all three 142 (14.0) 113 (12.6) 29 (25.2) 0.0006
positive for at least one 871 (86.0) 785 (87.4) 86 (74.8)
p53 IHC (n=1065)
negative 843 (79.2) 754 (79.5) 89 (76.1)
positive 222 (20.8) 194 (20.5) 28 (23.9) 0.4
*Fisher's exact test  
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There was no association between ATM and ERBB2 expression alone, but ATM aberrant 
tumors were more often ER/PR/ERBB2-triple-negative than ATM normal tumors (Table 
5). The subset of ER/PR/ERBB2-triple-negative nonBRCA1/2 breast tumors showed a 
very tight correlation with aberrantly reduced ATM expression (p=0.0006) as well as 
with positive p53 immunostaining (p<0.00000001) compared to tumors expressing at 
least one of these receptors (Figure 6).  
 
No specific histopathologic characteristics differentiating ATM aberrant BRCA1 or 
BRCA2 tumors were seen (data not shown), but the number of tumors is probably too 
small to reveal any statistically significant difference.  
 
No difference was noted in the age of breast cancer diagnosis between patients with ATM 
aberrant and normal tumors; the mean age of diagnosis in all groups was 55 years among 
nonBRCA1/2 patients and 47 years among BRCA1 and BRCA2 mutation carrier patients. 
There was no significant difference in survival of the patients between normal and 




























































Figure 6. ATM and p53 expression in relation to BRCA1/2 status in breast carcinomas. 
a) ATM protein expression is aberrantly reduced or lost more frequently among BRCA1 
(p=0.0003) and BRCA2 (p=0.0009) than in nonBRCA1/2 tumors. 
b) ATM is more commonly deficient among the ER/PR/ERBB2-triple-negative subset of 
nonBRCA1/2 tumors (20%, 29/142) than in cases which express at least one of these 
markers (10%, 86/871) (p=0.0006). The triple-negative tumors are also more frequently 
p53 immunopositive than the other nonBRCA1/2 tumors (p<0.00000001). 
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5.2 RAD50 and breast cancer (IV) 
5.2.1 RAD50 mutation analysis 
Altogether eighteen sequence changes were found when the coding region and exon–
intron boundaries of the RAD50 gene were screened in 435 familial breast cancer cases 
from UK (Table 6). Six of the changes were intronic. Of the twelve exonic sequence 
changes, two were synonymous, nine were missense changes and one was a nonsense 
mutation, Q350X. In the 46 Finnish familial breast cancer patients screened, only one of 
the intronic changes, ivs20+35C>T, was found in one case. The exonic missense variants 
were evaluated for possible functional effect by SIFT and PolyPhen analysis which 
suggested that R193W, which was found in one UK breast cancer case and alters a key 
residue in the MRE11 binding segment, likely affects RAD50 function. R224H and 
R327H may affect RAD50 function but the other variants appear well tolerated by SIFT 
and PolyPhen analysis.  
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Table 6. RAD50 variants in UK and Finnish familial breast cancer cases and controls. 
RAD50  variants UK cases Finnish cases
Truncating mutations
  1048C>T Q350X 1/702 0/281*
  687delT 0/435 3/590**
Missense variants
  280A>C  I94L 6/435 0/46
  373G>A  V127I 1/435 0/46
  577C>T  R193W 1/435 0/46
  671G>A  R224H 1/435 0/46
  695C>A  A232D 1/435 0/46
  943G>T  V315L 2/435 0/46
  980G>A  R327H 1/435 0/46
  2177G>A  R726H 1/435 0/46
  2525T>C  V842A 1/435 0/46
Synonymous variants
  204C>T  H68H 1/435 0/46
  3879C>T  I1293I 5/435 0/46
Intronic variants
  ivs1+12G>A 1/435 0/46
  ivs9+73C>T 2/435 0/46
  ivs0+35C>T 2/435 1/46
  ivs20+49G>C 3/435 0/46
  ivs22-15delTTC 1/435 0/46
  ivs22+24A>G 10/435 0/46
*0/786 UK controls and 0/319 Finnish controls
**1/560 Finnish controls  
 
The Q350X mutation was found in a UK woman who developed bilateral breast cancer at 
43 years. The mutation was not present in her sister, who developed breast cancer at 73 
years. There was a history of breast cancer on the paternal side and ovarian cancer in the 
mother, but we were not able to examine whether or not either of these cases carried the 
mutation. To further evaluate the Q350X mutation, 267 additional UK familial breast 
cancer cases, 786 UK controls, 235 Finnish breast cancer cases and 319 Finnish controls 
were screened for it by direct sequencing or minisequencing, respectively. No further 
case or control with Q350X was identified.  
 
The 687delT mutation found in the Finnish population previously (Heikkinen et al. 2003) 
was evaluated among index cases from 590 Finnish breast cancer families and 560 
healthy population controls. The mutation was found in three familial patients (0.5%) and 
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one control sample (0.2%). It showed incomplete segregation with cancer in the families. 
In one family, the mutation was found in the index case diagnosed with breast cancer at 
48 years, and both of her sisters were also carriers; one was diagnosed with breast cancer 
at 52 years and the other was unaffected at 58 years. In another family, the index case 
carrying the mutation was diagnosed with breast cancer at 35 years and her affected 
mother (breast cancer at 48 years) was also a carrier. However, the maternal aunt of the 
index was an affected (breast cancer at 45 years) non-carrier. No other family member 
was available for testing from the third family.  
5.2.2 Protein expression analysis of RAD50 687delT 
Immunoblotting analysis of RAD50 protein in three 687delT carrier lymphoblast cell 
lines showed a decreased overall abundance of the full-length protein product, compared 
to a non-carrier lymphoblast cell line. In addition, the truncated protein form was not 
detected in lysates from the cell lines heterozygous for 687delT with any of the three 
antibodies, including an antibody prepared specifically against the N-terminus of RAD50, 
predicted to be preserved in the mutant protein. Analysis of RAD50 cDNA from the 
687delT carrier lymphoblast cell lines by direct sequencing showed that both alleles were 
expressed. However, the mutant allele was only barely detectable indicating a much 





Figure 7. cDNA sequence from a normal lymphoblast cell line (top) and a cell line 
heterozygous for RAD50 687delT (bottom). The RAD50 687delT mRNA transcript is 
present in the heterozygous cell line at a very low level compared to the wild-type 
RAD50 allele. Arrow shows the position of nucleotide 687T (Tommiska et al., 
unpublished). 
 
Immunohistochemical analysis of three breast tumors from 687delT mutation carriers 
showed normal subcellular localization of the RAD50 protein. The overall staining 
pattern was nuclear and the signal detected by this semi-quantitative 
immunohistochemistry approach seemed comparable in the three mutation carrier tumors, 
in a set of additional 25 familial breast carcinomas with apparently wild-type RAD50, in 
the control normal breast tissues (n=15, with both luminal epithelial and myoepithelial 
cells positive), and in most of the 27 sporadic breast tumors examined. On the other hand, 
a small subset of sporadic carcinomas (3 out of 27) showed grossly reduced abundance of 
the RAD50 protein. No obvious defects of either the MRE11 or NBS1 protein expression 
levels were detected among the 28 familial breast tumors examined for RAD50, in 
contrast to the three sporadic carcinomas that showed concomitant reduction in staining 
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of all three proteins of the MRN complex. No evidence of AI was seen in the RAD50 
687delT mutation carrier tumor studied (data not shown).  
5.3 p53 R72P polymorphism and breast cancer (V) 
5.3.1 R72P and breast cancer risk 
The genotype frequencies of p53 R72P in the unselected and familial breast cancer 
patient series and population controls are shown in Table 7. The familial breast cancer 
patients were further divided in subgroups by strength of family history and inclusion of 
ovarian cancer. The distribution of the genotypes was closely similar in all the groups 
studied, with no deviation from the Hardy-Weinberg equilibrium among the 733 
population controls or among the total of 1551 breast cancer patients studied (p=0.91), or 
among any subgroups.  
 
Table 7. p53 R72P genotype frequencies among population controls, and unselected and 
familial breast cancer patients, by family history. 
Study subjects total RR RP PP
population controls 733 403 55.0% 278 37.9% 52 7.1%
all breast cancer patients 1551 825 53.2% 617 39.8% 109 7.0%
unselected breast cancer patients 858 459 53.5% 336 39.2% 63 7.3%
familial breast cancer patients* 923 478 51.8% 385 41.7% 60 6.5%
breast cancer only 793 401 50.6% 337 42.5% 55 6.9%
including also ovarian cancer 130 77 59.2% 48 36.9% 5 3.8%
index with only one affected first-degree relative 526 263 50.0% 231 43.9% 32 6.1%
three or more affected in the family 397 215 54.2% 154 38.8% 28 7.1%
*230 familial patients also belong to the series of unselected breast cancer patients  
 
The mean age at diagnosis for the RR homozygotes was 56.5 years, for RP heterozygotes 
56.6 years, and for PP homozygotes 56.8 years among the unselected patients, and 54.5, 
54.9, and 56.4 among the familial patients, respectively. No association of any of the 
genotypes with bilateral breast cancer or multiple cancers (breast cancer and at least one 
other non-breast cancer) was seen.  
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Among the BRCA1 and BRCA2 mutation carriers, the mean age at diagnosis for BRCA1 
carriers with RR genotype (n=25) was 42.6 years, for RP heterozygotes 44.9 years, and 
for PP homozygotes 48.7, and for patients carrying a P allele (RP or PP) (n=24) 45.8 
years. The mean ages at diagnosis for BRCA2 carriers were 50.1, 42.9, and 45.1, 
respectively. BRCA2 mutation carrier patients with a P allele (n=23) tended to be 
diagnosed at a younger age than RR homozygotes (n=25): mean age at diagnosis was 
43.3 years and 50.1 years, respectively (p=0.03, t-test for equality of means). No 
association of any genotype with bilateral breast cancer or multiple cancers among the 
BRCA1/2 mutation carriers was seen.  
5.3.2 R72P and histopathologic features of breast tumors 
Analysis of the histopathologic features of the breast tumors from unselected breast 
cancer patients with different R72P genotypes showed that the different alleles were 
associated with specific histologic features of the tumors. Tumor histology of the PP 
homozygotes was significantly more often lobular than tumor histology of the other 
genotypes; the tumors of the RR homozygotes and heterozygotes had more often ductal 
histology (p=0.004) (Table 8). Carriers of the R allele also tended to have more often 
grade 3 tumors than PP homozygotes while PP homozygotes had more frequently grade 1 
tumors (p=0.029). No association with hormone receptor status (ER and PR) or TNM 
stage was observed. The R72P genotype did not correlate with p53 expression as 
evaluated by immunohistochemistry. All these results were similar also among patients 
diagnosed below or at or over 50 years of age (data not shown).  
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Table 8. Tumor characteristics of unselected breast cancer patients with different p53 
R72P genotypes. 
Total (%) RR RP PP p
Tumor histology (n=852)
Ductal carcinoma 664 (77.9) 361 (79.0) 263 (79.9) 40 (60.6) 0.004
Lobular carcinoma 138 (16.2) 65 (14.2) 55 (16.7) 18 (27.3) 0.004
Medullary carcinoma 13 (1.5) 8 (1.8) 3 (0.9) 2 (3.0) ns
Other 37 (4.3) 23 (5.0) 8 (2.4) 6 (9.1) ns
Grade (n=809)
1 221 (27.3) 110 (25.2) 88 (28.4) 23 (37.1) 0.029
2 349 (43.1) 198 (45.3) 124 (40.0) 27 (43.5) ns
3 239 (29.5) 129 (29.5) 98 (31.6) 12 (19.4) 0.029
T (n=878)
1 536 (61.0) 283 (60.6) 210 (61.0) 43 (64.2) ns
2+3+4 342 (39.0) 184 (39.4) 134 (39.0) 24 (35.8) ns
N (n=868)
negative (0) 470 (54.1) 246 (52.7) 185 (55.1) 39 (60.0) ns
positive (1+2+3) 398 (45.9) 221 (47.4) 151 (45.0) 26 (40.0 ) ns
M (n=862)
negative 823 (95.5) 441 (95.2) 321 (96.1) 61 (93.8) ns
positive 39 (4.5) 22 (4.8) 13 (3.9) 4 (6.2) ns
ER status (n=852)
positive 671 (78.8) 347 (76.9) 276 (81.7) 48 (76.2) ns
negative 181 (21.2) 104 (23.1) 62 (18.3) 15 (23.8) ns
PR status (n=853)
positive 580 (68.0) 293 (65.0) 244 (72.0) 43 (68.3) ns
negative 273 (32.0) 158 (35.0) 95 (28.0) 20 (31.7) ns
p53 IHC (n=650)
positive 131 (20.2) 70 (20.2) 53 (20.8) 8 (16.7) ns
negative 519 (79.8) 277 (79.8) 202 (79.2) 40 (83.3) ns  
5.3.3 R72P and survival of breast cancer patients 
Kaplan-Meier survival analysis showed that unselected breast cancer patients with PP 
homozygous genotype had poorer survival than patients with other genotypes: cumulative 
survival at 80 months follow-up was 74% and 88%, respectively (p=0.003, log-rank test, 
n=621) (Figure 8). This was more pronounced when only patients with p53-negative 
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tumors were compared (p=0.001, n=356). For comparison, cumulative survival at 80 
months follow-up was 74% among patients with p53-positive tumors and 92% among 
patients with p53-negative tumors (p<0.001, n=457).  
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Figure 8. Kaplan-Meier survival curves of unselected breast cancer patients. 
a) survival among all patients by R72P genotype (PP homozygotes vs. other genotypes) 
b) survival among patients with p53 immunonegative tumors by R72P genotype 
c) for comparison, survival among all patients by p53 expression 
 
Multivariate analysis by Cox’s proportional-hazards regression model indicated tumor 
diameter (T), lymph node status (N), progesterone receptor expression (PR), p53 
expression, and PP homozygous genotype as independent prognostic factors among the 
breast cancer patients with information of these parameters available (n=373) (Table 9.).  
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Table 9. Multivariable analysis (Cox's proportional-hazards model) of prognostic factors 
in unselected breast cancer patients (n=373). 
Variables Risk ratio (95% CI) p
Age at diagnosis 1.0 (1.0-1.0) 0.5
T
2 vs. 1 1.1 (0.5-2.3) 0.8
3 vs. 1 2.7 (0.7-10.0) 0.1
4 vs. 1 8.5 (2.5-29.2) 0.001
N
1 vs. 0 6.5 (2.7-16.0) <0.001
2 vs. 0 21.3 (4.7-97.1) <0.001
M (pos. vs. neg.) 4.9 (1.8-13.2) 0.002
Grade
2 vs. 1 3.1 (0.4-24.6) 0.3
3 vs. 1 8.8 (1.1-72.4) 0.04
ER status (pos. vs. neg.) 1.9 (0.7-5.2) 0.2
PR status (pos. vs. neg.) 0.2 (0.1-0.5) <0.001
p53 IHC (pos. vs. neg.) 3.4 (1.7-6.9) 0.001
p53 R72P (PP vs. RP and RR) 2.1 (1.4-3.3) 0.001  
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6 DISCUSSION 
6.1 ATM and breast cancer (I, II, III) 
6.1.1 ATM variants in breast cancer 
Of the seven ATM mutations originally identified in Finnish A-T patients (Laake et al. 
2000, Allinen et al. 2002), only two, 6903insA and 7570G>C, seem to be associated with 
familial breast cancer susceptibility in Finland. Besides these, another ATM mutation, 
8734A>G, previously associated with breast cancer susceptibility (Thorstenson et al. 
2003, Teraoka et al. 2001), was observed in two families. In Finland, 6903insA, 
7570G>C and 8734A>G have been observed altogether in 9/630 breast cancer families 
(p=0.0003, OR 18.9, 95% CI 2.4-149.7, compared to healthy controls) (Allinen et al. 
2002, I). However, incomplete segregation of the mutations in the families (both 
unaffected mutation carriers and mutation-negative breast cancer patients were observed) 
and the fact that 6903insA and 7570G>C have also been observed in breast cancer 
patients without known family history of the disease (7/1209, p=0.03, OR 7.6, 95% CI 
0.9-61.9), and 7570G>C also in one healthy control, suggest incomplete penetrance for 
these mutations. Overall, the observed ATM mutations seem to explain only a small 
fraction of hereditary susceptibility to breast cancer in Finland, as they have been 
observed in 1.4% of the familial and 0.6% of the unselected cases studied so far. 
However, due to geographical clustering, their contribution to familial breast cancer in 
certain regions might be significant. In particular, the 6903insA and 8734A>G mutations 
cluster to the area of Tampere, and together their frequency in the breast cancer families 
studied from this region is 3.0% (5/168). In contrast, 7570G>C mainly concentrates to 
the Oulu region. In the Helsinki series, 7570G>C was the only mutation observed, in one 
familial case.  
 
Consistent with previous findings (Broeks et al. 2000), none of the mutation carrier 
tumors tested showed loss of the wild-type allele, indicating that LOH is not involved in 
development of breast cancer in ATM mutation carriers. Instead of the complete loss of 
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normal protein, it has been suggested that mutations with dominant-negative effect are 
the ones mainly responsible for the increased risk of breast cancer in ATM mutation 
carriers (Chenevix-Trench et al. 2002). Analysis of the 7570G>C heterozygous cell line 
showed that substitution of the evolutionarily conserved Ala2524 residue with proline in 
the FAT domain (Bosotti et al. 2000) leads to a stable protein with defective kinase 
activity. Failure in correct folding due to this substitution could inactivate kinase 
functions (Lavin et al. 2004), which would lead to the defective phosphorylation of ATM 
Ser1981 and the two ATM downstream targets p53 Ser15 and CHEK1 Ser317, and 
explain the pathogenicity of 7570G>C. The other observed A-T mutation, 6903insA, 
causes a frameshift. No truncated protein was present in the carrier cell lines, indicating 
that if translated, the mutant protein is unstable, and the total amount of endogenous 
ATM was reduced to about half. This seems sufficient for normal function of the ATM 
checkpoint signaling pathway, but not to ensure normal level of cell survival after IR-
induced damage. Different biological endpoints and functions could have different 
threshold requirements for ATM, which also has been reported previously (Delia et al. 
2000, Fernet et al. 2004). Thus, even though one cellular pathway that might promote 
tumorigenesis is altered, others may function apparently normally. Accordingly, instead 
of the dominant-negative effect, haploinsufficiency might be a more plausible 
explanation for the cancer susceptibility associated with 6903insA. The third potentially 
pathogenic ATM mutation, 8734A>G, leads to Arg2912Gly substitution in the kinase 
domain. The carrier cell lines showed no defects in the phosphorylation of ATM Ser1981 
or p53 Ser15, whereas CHEK1 Ser317 phosphorylation was impaired. Thus, Arg2912Gly 
substitution does not impair the phosphorylation of all ATM substrates, and the cancer 
predisposing effect of this mutation is not a dominant-negative one. Nevertheless, 
Arg2912Gly may impair some other protein-protein interactions required for optimal 
ATM kinase activity.  
 
Screening of the whole coding region of the ATM gene in 47 familial breast cancer 
patients from Southern Finland revealed altogether 17 different sequence variants, 
forming 17 different haplotypes. Of the 17 variants identified, seven were intronic, four 
were silent, and six were missense changes. All the intronic and silent changes have been 
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reported previously. One of the intronic changes, ivs10-6T>G, a known A-T mutation 
leading to incorrect splicing of the exon 11 and premature truncation of the protein (Dörk 
et al. 2001), has been suggested to associate with breast cancer in different populations 
(Thorstenson et al. 2003, Broeks et al. 2000, Chenevix-Trench et al. 2002), but larger 
case-control studies have not found a significant difference in frequencies between breast 
cancer cases and healthy controls (Szabo et al. 2004, Lindeman et al. 2004, Thompson et 
al. 2005). In our study, ivs10-6T>G was found in one of 265 familial breast cancer cases, 
and not in 228 controls, but the mutation did not segregate with cancer in the family. One 
of the five rare missense variants identified, 2119T>C (S707P), has been very extensively 
evaluated for breast cancer risk previously (Dörk et al. 2001, Spurdle et al. 2002, Sommer 
et al. 2003, Bretsky et al. 2003), and the results do not support its association with breast 
cancer. All the four rare missense variants studied further, 1814A>G (H605R), 4424A>G 
(Y1457C), 6539G>T (G2180V), and 998C>T (S333F), may affect ATM function as 
suggested by bioinformatic analysis. Three of these variants were very rare, each 
identified in only one out of over 250 cases while not in population controls. The 
1814A>G variant has previously been found also in a Danish breast cancer patient 
(Børresen-Dale, unpublished), whereas the 4424A>G variant has been found in a healthy 
population control, but not among breast cancer patients (Sommer et al. 2003). To our 
knowledge, the 6539G>T variant has not been reported previously. Even if these variants 
have a functional effect on the ATM protein, and are possibly pathogenic, their rarity 
limits the potential contribution to breast cancer susceptibility. The 998C>T was found in 
0.92% of the cases and in 0.83% of the controls, not supporting an association with breast 
cancer.  
 
The common polymorphism, ATMex39 5557G>A (D1853N), has been reported in the 
homozygous state to associate with enhanced clinical radiosensitivity in breast cancer 
patients (Angèle et al. 2003a), suggesting that it might be considered as a risk factor 
predisposing to adverse reactions after radiotherapy and supporting a possible functional 
effect for this variant. Heikkinen et al. (2005) recently reported that the ATMivs38 -8T>C 
polymorphism occurring in cis position with 5557G>A was associated with bilateral 
breast cancer among altogether 176 familial breast cancer patients studied. The combined 
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variant was found to associate also with reduction of ATM protein level in lymphoblast 
cells. No aberrant transcripts were detected (Heikkinen et al. 2005), although it was 
hypothesized that the 5557G>A variant previously suggested to affect an exonic splicing 
enhancer element (Thorstenson et al. 2003), together with the ivs38-8T>C change, could 
have some effect on the correct splicing of the exon 39. Most recently, Langholz et al. 
(2006) reported that the association of ivs38-8T>C with bilateral breast cancer could not 
be replicated in the WECARE Study population of 708 asynchronous bilateral and 1397 
unilateral breast cancer patients. While this does not support the previously suggested 
association of the ivs38-8T>C variant with bilateral breast cancer, Langholz et al. (2006) 
discussed the possibility that the variants studied may not be the causative alleles but may 
be contained in the same risk haplotype with other, possible risk alleles unique to the 
Finnish population. The WECARE cases were also unselected for family history, while 
those in the study by Heikkinen et al. (2005) belonged to breast cancer families. In our 
study, including about 800 unselected as well as almost 800 familial Finnish breast 
cancer cases, neither 5557G>A nor ivs38-8T>C, or any haplotype containing these 
variants in the Finnish population, was associated with breast cancer risk or bilateral 
breast cancer in any of the patient groups or subgoups studied. Among our familial breast 
cancer patients screened for the whole ATM gene, both of the variants 5557G>A and 
ivs38-8T>C were present in altogether three haplotypes. Our results suggest that the 
haplotype containing only the combined variant 5557G>A/ivs38-8T>C is not associated 
with bilateral breast cancer, and the two other haplotypes are far too rare to underlie the 
suggested association with bilateral breast cancer. The carrier frequency of the ivs38-
8T>C variant (or the combined variant, as all the carriers of ivs38-8T>C also carried 
5557G>A) was marginally higher in familial breast cancer patients, especially in those 
patients with only a moderate family history of breast cancer (8.1%), than in healthy 
controls (5.6%), but the difference did not reach statistical significance. Our results do 
not support an association of the variants with increased breast cancer risk in any of the 
patient groups studied, although small increases in risk cannot be excluded. However, our 
results are consistent with those by Langholz et al. (2006), who also found no association 
of the 5557G>A/ivs38-8T>C variant with bilateral breast cancer (OR=1, 95% CI 0.6-
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1.5). The variants were not significantly associated (together or alone) with multiple 
primary tumors, either.  
 
In conclusion, our results support the association of two A-T-related ATM mutations, 
6903insA and 7570G>C, in addition to 8734A>G, with breast cancer susceptibility. This 
is consistent with the study of Renwick et al. (2006), reporting an approximately two-fold 
increase in risk of breast cancer associated with ATM mutations causing A-T. This risk 
appears to be similar to that of low-penetrance susceptibility allele CHEK2 1100delC. No 
evidence that other classes of ATM variants confer a risk of breast cancer was found in 
the UK (Renwick et al. 2006), Southern Finnish (II), or Northern Finnish patients 
(Heikkinen et al. 2005). Another A-T causing mutation, 7271T>G (Val2424Gly), was 
also recently evaluated in a large study of breast cancer patients from Northern America 
and Australia, and it was suggested to be associated with high risk (up to 14-fold 
increase) of breast cancer (Bernstein et al. 2006). In addition, our results do not support 
an association of 5557G>A or ivs38-8T>C variant, or any haplotype containing these in 
the Finnish population, with bilateral breast cancer or with increased breast cancer risk. 
Our results also provide evidence for founder effects in the geographical distribution of 
A-T-related breast cancer susceptibility alleles. They cluster to specific regions in 
Northern and Central Finland, but in Southern Finland ATM mutations seem to have a 
minor effect, if any, on familial breast cancer risk. The incomplete penetrance of the 
mutations implies that the breast cancer risk associated with them is likely to depend on 
environmental factors and/or susceptibility alleles in other genes, as suggested by the 
polygenic model for breast cancer susceptibility (Pharoah et al. 2002). Of these 
mutations, 7570G>C and 8734A>G lead to amino acid substitutions, but only 7570G>C 
showed dominant-negative effect on kinase activity. For ATM 6903insA carriers, 
haploinsufficiency might be a more plausible explanation for the predisposition to cancer. 
Consequently, breast cancer susceptibility is not restricted to ATM mutations with 
dominant-negative effect on the kinase activity.  
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6.1.2 ATM expression in breast cancer 
ATM protein expression was reduced in 10.7% of all nonBRCA1/2 breast cancer tumors, 
and no difference was noted between sporadic (10.9%) and familial nonBRCA1/2 tumors 
(10.5%). Reduced ATM expression has been reported in 25-85% of sporadic breast 
cancer tumors previously. However, these studies have been small (including 17-106 
cases), and used various immunohistochemical methods and different interpretation and 
cut-off levels (Kairous et al. 1999, Angèle et al. 2000, Ding et al. 2004, Angèle et al. 
2003, Honrado et al. 2005b, Cuatrecasas et al. 2006). We employed an established 
immunohistochemical protocol (Lukas et al. 2001, Vahteristo et al. 2002) using the 
monoclonal ATM antibody previously validated for immunostaining on archival 
specimens of formalin-fixed, paraffin-embedded human tissues (Angèle et al. 2003, 
Bartkova et al. 2005a, 2005b). ATM protein expression in familial breast cancer tumors 
has previously been evaluated in only one study with a small number of cases. Honrado 
et al. (2005b) studied 46 familial nonBRCA1/2 tumors and found no significant difference 
in ATM expression between familial (nonBRCA1/2 or BRCA1/2) and sporadic tumors.  
 
Whereas the familial and the sporadic nonBRCA1/2 tumors showed similar ATM 
expression, there was a clear, approximately 3-fold increase of the ATM aberrant cases 
among both the BRCA1 and BRCA2 tumors, as compared to the nonBRCA1/2 tumors. 
ATM expression was significantly more often reduced in tumors from BRCA1 mutation 
carriers (33.3%) and in tumors from BRCA2 mutation carriers (30.0%), than in non-
BRCA1/2 tumors (10.7%). In only one of the previous studies (Honrado et al. 2005b) also 
BRCA1 tumors (n=33), BRCA2 tumors (n=24), and familial nonBRCA1/2 tumors (n=46) 
have been studied for ATM expression: in that study there was no significant difference 
in ATM expression between BRCA1/2 and nonBRCA1/2 tumors. The number of studied 
tumors was again smaller and the interpretation of the ATM expression very different.  
 
Aberrant ATM expression in nonBRCA1/2 breast cancer tumors was associated with 
negative hormone receptor (ER and PR) status and high grade of the tumor. Increased 
frequency of abnormal ATM expression in high-grade breast cancer tumors has been 
reported previously (Ding et al. 2004, Cuatrecasas et al. 2006). Cuatrecasas et al. (2006) 
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studied ATM expression in 52 breast carcinomas and reported that it associated with 
differentiation and angiogenesis, but they did not detect correlation between ATM 
expression and ER or PR status. We also examined the immunohistochemical expression 
of p53. There was no significant association of p53 overexpression with normal or 
aberrantly reduced ATM among the nonBRCA1/2 tumors. In BRCA1 tumors, the 
frequency of p53 immunopositivity was in general higher than in either BRCA2 cancers 
or in nonBRCA1/2 tumors, but these differences did not reach statistical significance, 
probably due to small sample size, as several studies have reported higher incidence of 
positive p53 immunostaining in BRCA1 tumors than in sporadic tumors; for BRCA2 the 
results have been less conclusive (Honrado et al. 2005). However, the subset of 
ER/PR/ERBB2-triple-negative nonBRCA1/2 breast tumors showed a very tight 
correlation with p53 immunopositivity compared to tumors expressing at least one of 
these receptors. p53 overabundance has been reported in the triple-negative subset of 
breast tumors previously (Cleator et al. 2007). Interestingly, also the aberrant reduction of 
ATM occurred significantly more commonly among the ER/PR/ERBB2-triple-negative 
tumors.  
 
Correlation of reduced ATM expression in breast carcinomas with tumor differentiation 
and hormone receptor status supports its role in cancer development and progression. The 
association of the aberrant ATM expression with these parameters was observed similarly 
both among the sporadic as well as familial breast tumors. These results suggest that 
ATM has a similar role in the progression of sporadic as well as familial tumors without 
BRCA1 or BRCA2 mutations. However, BRCA1/2 tumors showed more often reduced 
ATM expression, and so did the triple-negative subset of nonBRCA1/2 tumors. The 
triple-negative tumors are typically highly proliferative, poorly differentiated, and display 
extensive genetic instability. Interestingly, the triple-negative cancers share these, and 
multiple additional features with the BRCA1 breast tumors including high incidence of 
p53 mutations, broadly similar mRNA expression profiles, and poor prognosis (Cleator et 
al. 2007). Our results indicate that the increased frequency of aberrant ATM reduction 
may represent another feature shared by the triple-negative carcinomas and the tumors of 
the BRCA1 mutation carriers.  
 68 
 
ATM acts upstream of BRCA1 in the same pathway, since it directly phosphorylates 
BRCA1 on serine residues S1423 and S1524, thereby modulating the function of BRCA1 
(Cortez et al. 1999). The p53 tumor suppressor protein is also involved in the DNA 
damage repair and, like BRCA1, it is also a direct substrate of ATM (Kastan & Bartek 
2004, see also 2.4.3). Furthermore, both ATM and p53 have been found activated in early 
human pre-cancerous lesions as part of the suggested anti-cancer barrier (Bartkova et al. 
2005a). According to the concept of the DNA damage response (DDR) as an anti-cancer 
barrier (Bartkova et al. 2005a), there is constitutive activation of DNA damage 
checkpoints in pre-invasive human cancerous lesions, including breast lesions, and the 
subsequent selection for defects of various components of the DNA damage network is 
proposed to be a way to overcome this anti-cancer barrier during tumor progression. The 
subset of ATM-deficient tumors may reflect this. On the other hand, our results are 
consistent with the scenario where the initial cancer-predisposing defect, such as a 
BRCA1 or BRCA2 mutation, would impair the genome integrity control and lead to 
increased number of unrepaired DSBs, which in turn would activate the ATM-regulated 
cell-cycle checkpoints and cell-death pathways, ultimately leading to selection of ATM 
inactivation to overcome the anti-cancer barrier and progress towards malignancy. In 
contrast to normal tissue, the early cancerous lesions are exposed to oncogene-induced 
chronic replication stress and DNA breakage (Bartkova et al. 2005a, Gorgoulis et al. 
2005, Bartkova et al. 2006, Di Micco et al. 2006), and thus there is an increased demand 
for BRCA1/2 function in DNA damage signaling and repair. As a result, endogenous 
DNA damage in such pre-malignant lesions may no more be manageable by the DDR 
machinery with only one functional allele of BRCA1 or BRCA2. In other words, such 
conditions may unmask “conditional haploinsufficiency” for BRCA1/2 in the early 
lesions (Bartek et al. 2007). Under such conditions, the DDR machinery including the 
ATM-CHEK2-p53 cascade is activated, and this environment selects for inactivation of 
the activated DDR barrier, including ATM and p53. Thus, the BRCA1/2 defects would 
eventually lead to increased frequency of ATM inactivation, which is seen in the 
increased number of ATM aberrant carcinomas among the BRCA1/2 tumors. The actual 
molecular mechanisms behind low ATM expression in breast carcinomas are currently 
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unknown. Epigenetic silencing by promoter hypermethylation is one of the possible 
causes, but in a recent study, no methylation of the ATM promoter was found in 74 breast 
carcinomas studied (Treilleux et al. 2007). Genomic alterations of the promoter region 
could be another explanation, but have not been extensively studied. In addition, a 
reduction in the catalytic subunit of DNA-dependent protein kinase (DNA-PKcs) has 
been suggested to cause down-regulation of ATM, and a subset of tumors showed low 
levels of both DNA-PKcs and ATM, indicating that cross-regulation between DNA-PKcs 
and ATM could explain the reduced ATM levels seen in breast carcinomas (Treilleux et 
al. 2007).  
 
The ER/PR/ERBB2-triple-negative tumors are a challenge to treat (Cleator et al. 2007). 
The most exciting implication of identification of phenotypic and genetic similarities 
between BRCA1 and triple-negative breast tumors would be the emerging possibility to 
design novel targeted therapies to which both of these classes of breast cancer might be 
exceptionally sensitive. One promising treatment of BRCA1 tumors is small molecule-
mediated inhibition of PARP1, the key element of the pathways that repair DNA single 
strand breaks (SSBs). PARP1 inhibition renders cells particularly dependent on 
homologous recombination and therefore on BRCA1/2 function, resulting in high 
sensitivity of BRCA1/2 tumors (Bryant et al. 2005, Farmer et al. 2005), and enhanced 
sensitivity of cells with impaired DSB signaling (McCabe et al. 2006) to such treatment. 
This therapy may target not only the advanced cancers with complete lack of BRCA1/2 
function upon loss of the second allele of BRCA1/2, but also the conditionally deficient 
BRCA1/2-heterozygous cells in the precursor lesions with supra-threshold levels of 
endogenous DNA damage, while the normal tissues of the patients (including the 
BRCA1/2 mutation carriers) with sub-threshold levels of endogenous DNA damage 
would be resistant to such treatments.  
6.2 RAD50 and breast cancer (IV) 
The possible role of RAD50 in familial breast cancer predisposition is intriguing as 
RAD50 is part of the MRN complex and participates in critical cellular functions of DSB 
repair, functionally interacting with other breast cancer predisposition genes (van den 
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Bosch et al. 2003, Kastan & Bartek 2004). NBS1, another part of the MRN complex, has 
also been associated with breast cancer: NBS1 657del5 founder mutation has been 
reported to contribute significantly to the incidence of breast cancer in Poland (Gorski et 
al. 2003, Steffen et al. 2004, 2006), and NBS1 mutations have also been suggested to 
contribute to breast cancer in Northern Finland (Heikkinen et al. 2003, 2006). Our 
RAD50 mutation analysis in Southern Finnish and UK breast cancer families revealed 
only a single protein truncating mutation, Q350X, in one of the 481 breast cancer families 
studied. The mutation leads to truncation of 962 amino acids of the RAD50 protein, 
including most of the coiled-coil domain, the zinc-hook structure, and the C-terminal 
ATP-binding domain (Hopfner et al. 2001, Hopfner et al. 2002, Moncalian et al. 2004). 
No other case or control with the mutation was identified in the altogether 1488 UK 
samples and 600 Finnish samples analyzed. Therefore, even if RAD50 Q350X is 
contributing to cancer predisposition in the UK family in which it was identified, due to 
its rarity it cannot be making a major contribution to familial breast cancer overall.  
 
We identified altogether nine missense variants, two synonymous changes, and six 
intronic RAD50 variants. Only one intronic variant (ivs20+35C>T) was found in one of 
the 46 Finnish patients screened. Two of the missense variants (I94L and R224H) and 
one of the synonymous changes (H68H) found in UK patients had been reported 
previously in breast cancer cases from Northern Finland; both variants were also present 
in healthy controls, although at lower frequency (Heikkinen et al. 2003). The I94L and 
R224H variants affect conserved residues; I94L in the aminoterminal ATPase domain 
and R224H in the coiled-coil domain (Hopfner et al. 2000, Hopfner et al. 2001). 
However, the I94L and R224H variants have more recently been studied in additional 
breast cancer cases from Northern Finland, and the frequency of R224H in unselected 
breast cancer patients (2/317, 0.6%) did not differ from the frequency in controls (9/1000, 
0.9%), and I94L was not detected in those 317 cases (Heikkinen et al. 2006). R224H was 
not present among 80 families studied from Southern Finland (Tommiska et al., 
unpublished). In addition to R224H, two other variants, R913W, located in the N-
terminal MRE11 binding coiled-coil segment of the protein (Hopfner et al. 2001), and 
R327H may also affect RAD50 function according to SIFT and PolyPhen analysis. 
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However, there is no strong evidence to suggest that any of these variants are breast 
cancer susceptibility alleles. All are rare, limiting any potential contribution to breast 
cancer susceptibility, even if they are pathogenic, and due to the rarity of these variants it 
is not possible to evaluate their significance for familial breast cancer risk by a case-
control analysis.  
 
The protein truncating mutation 687delT was detected in 3/590 (0.5%) Southern Finnish 
familial breast cancer cases and 1/560 controls (0.2%), but was not present in the 435 UK 
families studied. The mutation showed incomplete segregation with cancer in the 
families, which is consistent with previous data showing that RAD50 687delT did not 
segregate with cancer in one of the two Northern Finnish families in which it was 
identified; the family also carried a pathogenic BRCA1 mutation (Heikkinen et al. 2003). 
RAD50 687delT was recently observed significantly more often in unselected breast 
cancer cases from Northern Finland (8/317, 2.5%) than in controls (6/1000, 0.6%, 
p=0.008). The frequency of carriers among cases was four-fold compared to that in 
controls. No difference was noted in frequencies between patients with or without family 
history of breast and/or ovarian cancer (Heikkinen et al. 2006). This and the incomplete 
segregation of the mutation with cancer in the families suggest that RAD50 687delT may 
be a low-penetrance breast cancer susceptibility allele (Heikkinen et al. 2006, IV). No 
RAD50 687delT carrier was found in altogether 512 breast cancer cases from Sweden, 
Norway and Iceland screened by Heikkinen et al. (2006). In our study, the mutation was 
not detected in the UK patients. Together these data suggest that RAD50 687delT is a 
Finnish founder mutation, and more prevalent in Northern Finland than in Southern 
Finland. Differences in prevalence of breast cancer susceptibility alleles between 
Northern and Southern Finland have been observed also with BRCA1, BRCA2, and ATM 
(Sarantaus et al. 2000, I). Common origin of the RAD50 687delT founder mutation was 
also supported by haplotype analysis in the Northern Finnish carriers (Heikkinen et al. 
2006).  
 
To investigate the functional effect of RAD50 687delT we studied RAD50 expression in 
lymphoblast cell lines from mutation carriers. This showed that the 687delT allele was 
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present in the mRNA pool, but at a very low level compared to the wild-type allele 
(Tommiska et al., unpublished), possibly due to partial degradation of the mutant mRNA 
by nonsense-mediated mRNA decay (NMD). The truncated protein was not detected on 
immunoblotting suggesting that, if translated, the residual truncated form is unstable. 
RAD50 687delT thus appears to be a null allele with no detectable expression of the 
mutant protein. This would enable formation of normal RAD50/MRE11 heterotetramers, 
suggesting the mutation is unlikely to have a dominant-negative effect on RAD50 
function.  
 
RAD50 protein expression and nuclear localization appeared normal in breast tumors 
from 687delT mutation carriers, suggesting that the wild-type allele was retained and 
expressed. In addition, no evidence of allelic imbalance was seen in the 687delT mutation 
carrier tumor studied by direct sequencing of the DNA. Our data are consistent with LOH 
analyses in breast tumors from previously reported 687delT carriers, which demonstrated 
that the wild-type allele was not lost (Heikkinen at al. 2003). This was also confirmed in 
the recent study by Heikkinen et al. (2006). Our semi-quantitative immunostaining results 
cannot exclude a moderate deficit of some 20-50% of the overall RAD50 protein in the 
breast tumors from 687delT mutation carriers. In addition, the overall amount of RAD50 
in lymphoblast cells heterozygous for 687delT was reduced compared to that in non-
carrier cells. Together these data suggest that RAD50 is not acting as a classical tumor 
suppressor gene in breast cancer, but it is possible that RAD50 haploinsufficiency is 
contributing to cancer. Haploinsufficiency has been suggested by mouse models for also 
other important DDR proteins whose defects contribute to tumorigenesis, for example the 
tumor suppressor Chk1 kinase (Lam et al. 2004). The CHEK2 1100delC low-penetrance 
breast cancer susceptibility allele has also been suggested to act by haploinsufficiency 
(Jekimovs et al. 2005, Sodha et al. 2006), and the tumorigenesis associated with A-T –
related ATM mutation 6903insA is also likely to be due to haploinsufficiency (I). Work 
using genetically modified mice imply that even subtle hypomorphism in the Rad50 
function is sufficient to cause severe pathological consequences including predisposition 
to cancer (Bender et al. 2002). The tumor-prone phenotype of mice with hypomorphic 
Rad50 mutations indicates that RAD50 haploinsufficiency might contribute to human 
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breast tumorigenesis, although with low penetrance due to the remaining functional 
allele.  
 
Cytogenetic analysis of peripheral blood T-lymphocytes of Northern Finnish 687delT 
carriers revealed more chromosomal rearrangements, both simple and complex, than in 
healthy non-carrier controls. The increased genomic instability of mutation carriers 
suggests an effect for RAD50 haploinsufficiency on genomic integrity (Heikkinen at al. 
2006). Another RAD50 mutation, ivs3-1G>A, leading to incorrect splicing and thus to a 
premature stop codon, and also associated with genomic instability, was also found in 
Northern Finland (Heikkinen et al 2006). In conclusion, germline variants in the RAD50 
gene do occur in familial breast cancer patients, yet they are very rare. RAD50 687delT is 
a Finnish founder mutation with low penetrance, and more prevalent in Northern Finland 
than in Southern Finland where RAD50 can only be making a minor contribution to 
familial breast cancer predisposition. Among reasons for the overall low frequency of 
RAD50 germline mutations might be the essential role of RAD50 in embryogenesis: 
homozygous Rad50 gene deletions in mouse models result in early embryonic lethality 
(Luo et al. 1999), suggesting that RAD50 plays an essential role in genome maintenance 
and defects in its function are not tolerated.  
 
The abundance and localization of RAD50 appeared normal in all the 28 familial breast 
tumors examined by immunohistochemistry, and this was the case also for the MRE11 
and NBS1 proteins. The fact that we identified a small subset of sporadic breast tumors 
with a simultaneous gross reduction of all three proteins of the MRN complex is 
consistent with a previous study of sporadic carcinomas (Angèle et al. 2003). 
Furthermore, the latter cases also document that the antibodies and our assay conditions 
were appropriate to detect such aberrations at the protein level when they existed. The 
subset of MRN-deficient carcinomas may again (as the subset of ATM-deficient 
carcinomas in III) reflect the selection for defects of the components of the activated 
DDR network as a way to overcome the anti-cancer barrier during tumor progression 
(Bartkova et al. 2005a).  
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6.3 p53 R72P and breast cancer (V) 
The studies on p53 R72P polymorphism and breast cancer risk have yielded inconsistent, 
even contradictory results (see 2.6.3). We aimed to evaluate whether R72P associates 
with increased risk for breast cancer among extensive sets of 923 familial and 858 
unselected breast cancer patients and 733 population controls. The genotype frequencies 
among all patient series, as well as in subgroups defined by different family history, 
bilateral breast cancer or multiple cancers, were closely similar. Similarly, no difference 
in the age at diagnosis was seen by R72P genotype. Our results thus indicate that the p53 
R72P genotypes are not associated with increased breast cancer risk among unselected or 
familial breast cancer patients. Our results have recently been confirmed in a large study 
of the Breast Cancer Association Consortium (BCAC), in which altogether 8,743 breast 
cancer cases and 10,618 controls from Europe, the USA, Australia, and Asia, genotyped 
for R72P, were analyzed, and none of the genotypes was associated with increased breast 
cancer risk (Breast Cancer Association Consortium 2006).  
 
The R72P polymorphism has also been studied together with other polymorphisms in 
genes interacting with p53, as in addition to gene-environment interactions, also gene-
gene interactions may have an effect on cancer risk. The most extensively studied 
polymorphism possibly interacting with p53 R72P is MDM2 SNP309, a T to G change in 
the promoter region of the inhibitor of p53, causing attenuation of the p53 pathway and 
accelerated tumor formation in individuals carrying a germline p53 mutation (Bond et al. 
2004, Bond et al 2005, Bougeard et al. 2006, Ruijs et al. 2007). The p53 72Pro/Pro and 
MDM2 SNP309 G/G genotypes have been reported to associate, for example, with 
increased risk of esophageal squamous cell carcinoma (Hong et al. 2005) and lung 
cancer, where the interaction between the polymorphisms seemed to increase the risk in a 
multiplicative manner (Zhang et al. 2006). Bougeard et al. (2006) also suggested that the 
impact of the MDM2 SNP309 G allele on the age of tumor onset in germline p53 
mutation carriers could be amplified by the p53 R72 allele. Some indication of gene-gene 
interaction was observed in breast cancer, too, but no consistent direction of interaction 
was apparent (Cox DG et al. 2007). In the pooled data set of BCAC, no indication of 
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either an increase in risk or an earlier age at onset of breast cancer in carriers of either 
MDM2 SNP309 or p53 R72P or both was observed (Schmidt et al. 2007).  
 
We also evaluated R72P genotype frequencies and possible modifying effect on breast 
cancer risk among BRCA1 and BRCA2 mutation carriers. BRCA2 mutation carrier 
patients carrying a 72P allele (72P homozygotes and heterozygotes) tended to be 
diagnosed younger than the R72 homozygotes; Martin et al. (2003) found a similar trend 
among BRCA2 mutation carriers, but the difference was not statistically significant in 
either study. They also found that presence of a 72P allele was associated with an earlier 
age of breast cancer diagnosis among BRCA1 mutation carriers, which was not the case 
in our material. Association of R72 homozygous genotype with multiple primary cancers 
or family history of multiple primary cancers among BRCA1/2 mutation carrier women 
was also suggested by Martin et al. (2003), but no association of any of the genotypes 
with multiple cancers was seen in our study. As the numbers of BRCA1/2 mutation 
carrier patients in either study were quite small, larger studies will be needed to evaluate 
the possible modifying effect of R72P genotype on cancer risk among BRCA1 and 
BRCA2 mutation carriers. In the study including 447 Spanish BRCA1/2 mutation carriers, 
genotype and haplotype analyses revealed that the presence of a specific haplotype 
carrying the 72P allele and not carring the 16-bp insertion (c.97-147ins16bp) in p53 
intron 3, was associated with an earlier age of breast and/or ovarian cancer onset in 
BRCA2 mutation carriers. This result was also supported by functional studies, as cells 
carrying the haplotype with 72P and without the 16-bp insertion showed a decrease in 
p53 apoptotic rate (Osorio et al. 2006).  
 
Interestingly, analysis of histopathologic features of breast tumors suggested association 
of the R72P genotypes with different histologic types. The 72P homozygous breast 
cancer patients presented significantly more often with lobular carcinoma than patients 
carrying an R72 allele, and had often grade 1 tumors, whereas R72 allele carriers had 
more frequently ductal carcinomas and often grade 3 tumors. Association of 72P 
homozygosity with lower grade was only of borderline significance, but it would be 
consistent with a higher frequency of lobular carcinomas among 72P homozygous 
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patients, as lobular carcinomas have been found to be more often of lower grade 
(Molland et al. 2004). Other studies have examined the association of R72P 
polymorphism with histopathologic characteristics of breast tumors, too. Noma et al. 
(2004) found no significant association of different R72P genotypes with tumor 
histology, tumor size, or lymph node status in 191 Japanese breast cancer patients. In 
their study, too, the 72P homozygous patients tended to have tumors of lower grade, but 
the difference was not statistically significant. However, they observed that the tumors of 
the 72P homozygotes were significantly more often ER positive than the tumors of the 
R72 homozygotes, which was not seen in our 852 tumors. In an analysis of 664 Korean 
patients, no association with ER status, or histologic grade was seen, but carriers of the 
72P allele had significantly more often negative axillary lymph node status than the R72 
homozygotes (Han et al. 2004), which was not the case in Japanese or Finnish patients 
(Noma et al. 2004, V). In another Japanese study, no association of any of the genotypes 
with tumor size, node status, histology, grade, ER status or p53 expression was observed 
among 557 breast cancer patients (Toyama et al. 2007). Differences in patient selection 
criteria as well as in allele frequencies between different populations may have an impact 
on these results. Apparently the possible association of R72P with different 
histopathologic features of breast cancer tumors warrants further studies.  
 
Analysis of survival among unselected breast cancer patients revealed association of the 
genotypes with differential survival. No difference in survival has been found between 
patients with lobular and ductal infiltrating carcinomas (Molland et al. 2004), but p53 
72P homozygotes were found here to have a significantly poorer survival than R72 
homozygotes or heterozygotes (p=0.003). Because in our material the patients with p53 
immunopositive tumors did have significantly poorer survival, we excluded the effect of 
p53 positivity on survival by including only patients with p53 immunonegative tumors in 
the analysis. The effect of R72P on survival seemed to be independent of somatic p53 
mutations in the tumors, as the effect was similar when only patients with negative 
immunostaining for p53 on the tumors were included in the analysis (p=0.001). 
Multivariate analysis showed that 72P homozygous genotype was overall an independent 
prognostic factor, with a two-fold increased risk of death. As 8.2% of all patients were 
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homozygous for the 72P allele (8.1% among p53 negative cases), codon 72 genotype 
could be a useful additional prognostic marker among this subgroup of patients. The 
effect of 72P homozygous genotype on survival was similar both among patients with 
ductal and lobular carcinoma (data not shown). The fact that the effect of 72P 
homozygous genotype on survival is independent of somatic p53 mutations is also 
supported by findings that breast tumors of 72P homozygotes have a lower frequency of 
somatic p53 mutations than tumors of R72 homozygotes and heterozygotes (Langerød et 
al. 2002, Noma et al. 2004). These data suggest that the p53 Pro/Pro is functionally 
impaired per se, independently of somatic p53 mutations. Our finding is also consistent 
with the R72 variant of wild-type p53 being a more potent inducer of apoptosis than the 
wild-type 72P variant. It has been suggested that R72 homozygotes may respond more 
favorably to radiation or chemotherapy (Dumont et al. 2003), and the superior activity of 
wild-type R72 in inducing apoptosis is reflected in vivo in more favorable outcome in 
patients whose cancers express the wild-type R72 variant, compared to those with the 
wild-type 72P, and receiving chemo-radiotherapy for advanced squamous cell 
carcinomas of head and neck (SCCHN) (Sullivan et al. 2004). These favorable effects of 
R72 allele may, however, be reversed by a somatic p53 mutation on this allele, as has 
been reported in SCCHN (Bergamaschi et al. 2003, Schneider-Stock et al. 2004), and 
retention of the R72 allele with loss of the 72P allele in the tumor tissue has been 
associated with reduced survival in heterozygous breast cancer patients (Bonafè et al. 
2003). In one breast cancer study, the 72P allele has been suggested to have a protective 
effect against death, with borderline significance, but this effect was reduced by inclusion 
of known prognostic variables in the analysis (Goode et al. 2002). The effect of the 72P 
allele on poorer survival is supported, however, also by poorer survival of 72P allele 
carriers reported among colorectal and lung cancer patients (Starinsky et al. 2004, 
Mechanic et al. 2007). Also in ovarian cancer, the patients with the 72P tumor genotype 
have significantly poorer survival, but in association with non-missense or certain 
missense mutations in p53. On the contrary to breast cancer, in ovarian cancer the 72P 
allele is associated with higher frequency of p53 mutations, and p53 codon 72 genotype 
has an impact on the prognostic value of somatic p53 mutations (Wang et al. 2004, 2007).  
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Recently, supporting our results, in the study of 557 Japanese breast cancer patients, the 
72P homozygous genotype was associated with poorer disease-free survival (DSF). This 
association was especially significant in patients who had received adjuvant 
chemotherapy (Toyama et al. 2007). In addition, the 72P homozygous Chinese breast 
cancer patients were observed to be less sensitive to anthracycline-based chemotherapy 
than other genotypes (Xu et al. 2005). On the contrary, in the very recent study of 204 
Danish breast cancer patients, no association of the different R72P genotypes with DSF 
or the number of p53 mutations was found (Kyndi et al. 2006). Actually, Kyndi et al. 
(2006) proposed that LOH rather than R72P genotype would be associated with survival, 
as they observed a poorer survival among patients with retention of the 72P allele, a 
result completely opposite to the finding of Bonafè et al. (2003). However, both studies 
are based on a very limited number of patients, and larger studies are needed to clarify 
the role of R72P genotype, LOH, and p53 mutations and their interdependence on breast 
cancer survival. Unfortunately, survival studies are often difficult to compare with each 
other as different follow-up times and criteria (use of incident vs. prevalent cases or use 
of disease-specific vs. overall vs. disease-free survival), or stratification of the study 
population may be used, and all this may have a profound impact on the results. Also 
treatment regimens as well as allele frequencies vary between populations; 38% of 
Japanese breast cancer patients were homozygous for 72P (Toyama et al. 2007), 
compared to 8% of Finnish patients, for example, and genetic effects may only apply to a 
specific subgroup of patients, or in combination with other genetic polymorphisms. 
Furthermore, there is evidence of selective expression of the different alleles in R72P 
heterozygotes, and that this selective expression is dependent on ethnicity: healthy 
Caucasians were found to preferentially express the R72 allele whereas Asians 
preferentially expressed the 72P allele, and the situation was reversed in Asian 
heterozygous breast cancer patients, 75% of whom preferentially expressed the R72 allele 
(Siddique et al. 2005). The finding of codon 72 genotype as a prognostic factor in breast 
cancer warrants further studies, in different populations and especially taking into 
consideration also variations in other interacting genes.  
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7 SUMMARY AND CONCLUSIONS 
The role of ATM gene in breast cancer susceptibility has been under an extensive 
investigation and debate for over a decade. Recent data have clarified the picture to some 
extent and confirmed that the ATM mutations associated with A-T are also breast cancer 
susceptibility alleles. In Finland, too, only few A-T –related ATM mutations contribute to 
familial breast cancer. These founder mutations may be responsible for excess familial 
breast cancer regionally in Northern and Central Finland, but in Southern Finland our 
results suggest only a minor effect, if any, of any rare ATM genetic variants on familial 
breast cancer. Two common ATM polymorphisms studied were not associated with 
cancer risk, either. Functional studies of the founder mutations suggested that dominant-
negative effect is not the only mechanism with which ATM mutations are contributing to 
cancer; haploinsufficiency also seems to play a role in tumorigenesis associated with 
ATM mutations. The role of ATM in cancer development and progression was also 
supported by the results of the immunohistochemical studies of ATM expression, as 
reduced ATM expression in breast carcinomas was found to correlate with tumor 
differentiation and hormone receptor status. Aberrant ATM expression was also a feature 
shared by BRCA1/2 and ER/PR/ERBB2-triple-negative breast carcinomas, indicating that 
different selective pressures may operate in these carcinomas during tumor progression, 
compared to other nonBRCA1/2 tumors. This may also have an implication for treatment 
of these ATM aberrant carcinomas. From the clinical point of view, the DNA-damage-
threshold-related differences might be beneficial in response to therapy. The 
ER/PR/ERBB2-triple-negative breast carcinomas are a challenge to treat, and 
identification of phenotypic and genetic similarities between the BRCA1/2 and the triple-
negative breast tumors could have an implication in designing novel targeted therapies to 
which both of these classes of breast cancer might be exceptionally sensitive.  
 
Mutations of another plausible breast cancer susceptibility gene, RAD50, were found to 
be very rare, and RAD50 can only be making a minor contribution to familial breast 
cancer predisposition in UK and Southern Finland. The Finnish founder mutation RAD50 
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687delT seems to be a null allele and may carry a small increased risk of familial breast 
cancer. RAD50 is not acting as a classical tumor suppressor gene, but it is possible that 
RAD50 haploinsufficiency is contributing to cancer.  
 
In addition to relatively rare high- and low-penetrance breast cancer susceptibility alleles, 
common polymorphisms may also be associated with increased breast cancer risk. 
Furthermore, these polymorphisms may modify the cancer risk caused by the genes with 
which they interact, or have an impact on the progression and outcome of the disease, 
thus effecting the prognosis of the patient. Our results here suggest no effect of either 
allele of the common p53 R72P polymorphism on familial breast cancer risk or breast 
cancer risk in the population, but R72P seems to be associated with histopathologic 
features of the tumors and survival of the patients. Multivariate analysis showed that 72P 
homozygous genotype was overall an independent prognostic factor, with a two-fold 
increased risk of death. These results present important novel findings also with clinical 
significance, as codon 72 genotype could be a useful additional prognostic factor in 
breast cancer, especially among the subgroup of patients with wild-type p53 in their 
tumors. The role of 72P homozygous genotype as a prognostic and predictive marker in 
breast cancer warrants further studies.  
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